

CURRICULUM VITAE

NAME George Warren Booz, PhD, FAHA

CITIZENSHIP USA

ADDRESS

University of Mississippi Medical Center
Department of Pharmacology and Toxicology
2500 North State Street
Jackson, MS 39216-4505

- TEL: 601-984-4401
- FAX: 601-984-1637
- Email: gbooz@umc.edu

EDUCATION AND POST-GRADUATE TRAINING

| | | |
|-----------------------|-------------|--|
| B.S. in Biology | 1972 – 1976 | St. Joseph's University Philadelphia, PA |
| M.S. in Physiology | 1977 – 1981 | University of Pennsylvania Philadelphia, PA |
| Computer Science | 1983 – 1986 | Drexel University Evening College Philadelphia, PA |
| Ph.D. in Pharmacology | 1986 – 1990 | Thomas Jefferson University Philadelphia, PA |
| Postdoctoral Fellow | 9/90 – 6/94 | Weis Center for Research Geisinger Clinic Danville, PA |

NON-FACULTY POSITIONS

| | | |
|----------------------|-------------|--|
| Associate Scientist | 7/94 – 5/96 | Weis Center for Research Geisinger Clinic |
| Research Scientist-1 | 6/96 – 6/97 | Weis Center for Research Geisinger Clinic |

FACULTY POSITIONS

| | | |
|--------------------------------|---------------|--|
| Instructor | 7/97 – 6/98 | Department of Cellular and Molecular Physiology Pennsylvania State University College of Medicine Weis Center for Research |
| Assistant Professor | 6/98 – 5/99 | Department of Cellular and Molecular Physiology Pennsylvania State University Coll. of Med., Weis Center for Research |
| Assistant Professor | 5/99 – 9/02 | Department of Internal Medicine Texas A & M University System HSC College of Medicine Cardiovascular Research Institute |
| Research Physiologist (WOC) | 09/00 – 10/08 | Division of Molecular Cardiology The Central Texas Veterans Health Care System |

| | | |
|--|-------------------|--|
| Assistant Professor | 9/02 – 10/08 | Department of Internal Medicine Texas A & M University System HSC College of Medicine Cardiovascular Research Institute Division of Molecular Cardiology |
| Assistant Professor (cross-appointment) | 5/03 – 1/06 | Department of Medical Physiology Texas A & M University System HSC College of Medicine |
| Member | 6/03 – 10/08 | Pulmonary and Critical Care Medicine Scott & White Hospital and Clinics The Texas A & M University System HSC College of Medicine |
| Member | 10/03 – 10/08 | Graduate Faculty Texas A&M Univ. System HSC College of Medicine Medical Sciences Program |
| Assistant Professor (Adjunct) | 10/05 – 10/06 | Department of Biology University of Mary Hardin-Baylor Belton, TX |
| Associate Professor | 11/3/08 – 6/21 | Department of Pharmacology and Toxicology, The University of Mississippi Medical Center, School of Medicine |
| Professor | 7/21 - present | Department of Pharmacology and Toxicology, The University of Mississippi Medical Center, School of Medicine |
| Member | 1/13/09 – present | Graduate Faculty The University of Mississippi Medical Center, School of Graduate Studies in the Health Sciences |

RESEARCH SUPPORT

Submitted

4-1-2021 – 3-31-2026

The role of the IL-33/ILC2 axis in cardiac repair post-MI

NHLBI

PI: George W. Booz, PhD

Col: Fouad A. Zouein, PhD

Current

1R01AG057842 4-1-2019 – 1-31-2024

ADDUCIN, ACTIN CYTOSKELETON AND COGNITIVE IMPAIRMENTS

NATIONAL INSTITUTE ON AGING

PI: Fan Fan, MD

Col (20% effort): George W. Booz, PhD

Completed

| | |
|---------------------|--|
| 2018 – 2020 | Olav Raagholt og Gerd Meidel Raagholts, PDE9 Inhibition as a Novel Therapeutic Opportunity for Diastolic Dysfunction PI: Raffaele Altara, PhD Collaborator: George Booz, PhD |
| 7/1/08 – 6/30/14 | National Heart, Lung, and Blood Institute <i>Regulation of IL-6-Type Cytokine Cardioprotective Signaling in the Ischemic Heart</i> Principal Investigator: George Booz Co-Investigators: Roy Duhé, Mazen Kurdi Total Direct Costs: \$1,225,676 |
| 8/1/09 – 7/31/11 | National Heart, Lung, and Blood Institute Recovery Act Administrative Supplement to RO1: Postdoctoral Fellow Principal Investigator: George Booz Total Direct Costs: \$178,800 |
| 5/1/09 – 4/30/10 | Intramural Research Support Program <i>Antioxidant Hydrogel POSS-Catechin Nanocomposites for Stem Cell Cardiac Survival</i> Principal Investigator: George Booz Total Direct Costs: \$25,000 |
| 10/1/08 – 9/30/10 | ProStem Biotech Inc. <i>Improving the Therapeutic Potential of Umbilical Cord Blood Stem Cells for Cardiac Repair</i> Principal Investigator: George Booz Co-Investigator: Mazen Kurdi Total Direct Costs: \$240,000 Amount paid: \$64,000 |
| 6/1/07 – 5/31/08 | S&W Research Foundation Grant <i>Role of JAK signaling in diabetic cardiomyopathy</i> Principal Investigator: George Booz Co-Investigators: Syed Naqvi, Roy Duhe Total Direct Costs: \$40,000 |
| 11/17/06 – 11/16/07 | S&W Research Foundation Grant <i>Role of Calcitonin-Gene Related Peptide in Ischemia/Reperfusion Injury</i> Principal Investigator: Khurshed Katki Co-Investigators: Mazen Kurdi, George W. Booz Total Direct Costs: \$40,000 |
| 7/1/05 – 6/30/06 | S&W Research Foundation Grant <i>Regulation of Non-Small Cell Cancer Apoptosis by Interferon-γ</i> Principal Investigator: George Booz Co-Investigators: Richard E. Winn, Gagan Prakash Total Direct Costs: \$39,988 |
| 7/1/04 – 6/30/06 | American Heart Association, Texas Affiliate <i>Role of STAT3 in Defining IL-6 Signaling in Myocardial Infarction</i> Principal Investigator: George W. Booz Total Direct Costs: \$124,000 |
| 8/3/03 – 8/2/05 | VA VISN17 <i>STAT3 Transcriptional Regulation of Cardiac Myocyte Growth</i> |

3/1/04 – 2/28/05
Principal Investigator: George W. Booz
Total Direct Costs: \$100,000
S&W Research Foundation Grant
Antioncogenic Potential of GRIM-19 in Human Non-Small-Cell Lung Cancer Cells
Principal Investigator: Richard E. Winn
Co-Investigators: George Booz, Steve Maxwell, Christopher Spradley

10/1/03 – /30/04
Total Direct Costs: \$40,000
S&W Research Foundation Grant
Role of STAT Transcription Factors in Apoptosis of Human Non-Small-Cell Lung Cancer Cells
Principal Investigator: George W. Booz
Co-Investigator: Nikhat Salamat

7/1/99 – 6/30/03
Total Direct Costs: \$40,000
National Institutes of Health (HL44883)
Regulation of Cardiac Hypertrophy by Angiotensins.
Principal Investigator: Kenneth M. Baker
Co-Investigators: David E. Dostal, George W. Booz

7/1/98 – 6/30/03
Total Direct Costs: \$980,000
National Heart, Lung, and Blood Institute (HL58439)
Novel Signaling Pathways for Angiotensin II in The Heart
Principal Investigator: Kenneth M. Baker
Co-Investigator: George W. Booz

7/1/96 – 6/30/98
Total direct costs: \$999,457
American Heart Association, Pennsylvania Affiliate
Role of the AT2 Receptor in Angiotensin II-Induced Hypertrophy of Cardiac Myocytes
Principal Investigator, George W. Booz

9/1/94 – 8/31/95
Total Direct Costs: \$70,000
American Heart Association, Pennsylvania Affiliate
Relative Contribution of Protein Kinase C Isozymes to Hypertrophic Growth of Cardiac Myocytes
Principal Investigator, George W. Booz

7/1/91 – 6/30/94
Total Direct Costs: \$35,000
Total Direct Costs: \$25,000
National Heart, Lung, and Blood Institute
National Research Service Award, HL08477
Mechanisms of Angiotensin-Induced Cardiac Hypertrophy
Total Direct Costs: \$81,200

PUBLIC AND PROFESSIONAL SERVICE

Grant Reviewer (Ad hoc)

VA Merit Review Proposals, 1994 – 2000

U.S. Civilian Research & Development Foundation (CRDF), 2005

AIBS: US Army Medical Research and Materiel Command (USAMRMC), 2005 - 2007

FAMRI Center of Excellence Award, 2006

FAMRI Center of Excellence Award, 2006

FAMRI Re-Review, 2007

FAMRI Center of Excellence Award (Re-Review), 2012
FAMRI Richmond Center of Excellence progress report, 2013
FAMRI Richmond Center of Excellence progress report, 2014
FAMRI Richmond Center of Excellence progress report, 2015
National Medical Research Council (Singapore), 2006
The National Research Program on Cardiovascular Diseases (Inserm/French National Institute for Health and Medical Research) and The French Society of Arterial Hypertension, 2007
GENOPAT Program - Molecular Pathophysiology: From Rare to Common Diseases, Proposals submitted to French National Research Agency (Inserm/French National Institute for Health and Medical Research) in association with the French Association against Myopathies, 2009
Italian Ministry of Health, Directorate for Health and Technologies Research, 2009
Italian Ministry of Health, 'Young Italian Researchers Call', 2010
Italian Ministry of Health, 2011,2012,2013
French National Research Agency, "BlueSky and Young Researchers Programmes" 2011
French National Research Agency, Call for projects: White - SVSE 1 - Physiology, pathophysiology, public health, 2012
Pathophysiology Section of the French National Research Agency in the Exploratory and Emerging Research Department, 2013
French National Research Agency, generic call for proposals 2014: pre-proposal evaluation
CARIPARO Foundation, 2012
AIBS/FAMRI Clinical Innovator Award, 2012, 2013
Genomics and Immunology Research Laboratory within the USDA Beltsville Human Nutrition Research Center, project plan "Health promoting roles of food bio-active phenolic compounds on obesity-altered heart and kidney functions and physiology", 2013
The South Dakota State University College of Pharmacy, 2014
AHA Collaborative Science Award Letter of Intent, 2014
Italian Ministry of Health - National Call Biomedical Research, 2014
FY15 Peer Reviewed Medical Research Program (PRMRP) for the Department of Defense Congressionally Directed Medical Research Programs - Discovery Cardiovascular Health Center for Medicinal Cannabis Research (CMCR), University of California, San Diego, June 2020

Grant Review Panels

NHLBI Program Project Review Panel, Spring 2004
NHLBI Program Project Review Panel, Sept. 2004,
NHLBI Program Project Review Panel, Jan. 2005, Sept. 2005
NHLBI Program Project Review Panel, Feb. 2006, Sept. 2007
American Institute of Biological Sciences -
FAMRI (Flight Attendant Medical Research Institute):

- Panel - Molecular basis of cancers associated with second hand smoke: 2005
- Panel - Molecular basis of diseases (non-cancer) associated with second hand smoke: 2004, 2006, 2007
- Panel - Cardiovascular Diseases: 2008

American Heart Association
Cardiac Biology/Regulation - Basic & Clinical / Translational:
Region 3, Spring 2009 & Spring 2010
Region 2 and 3, Fall 2010
Region 2 and 3, Spring 2011
Region 2 and 3, Fall 2011

Region 2 and 3, Spring 2012
Cardiac Bio BSc 1: Fall 2012
Cardiac Bio Reg - BSci 3: Spring, 2013 (co-chairperson)
Cardiac Bio Reg - BSci 3: Fall, 2013 (co-chairperson)
Cardiac Bio Reg - BSci 3: Spring, 2014 (co-chairperson)
Cardiac Bio Reg - BSci 6: Fall, 2014 (co-chairperson)
Cardiac Bio Reg - BSci 3: Spring, 2015 (chairperson)
Cardiac Bio Reg - BSci 3: Spring, 2016 (chairperson)
Cardiac Bio Reg - BSci 3: Fall, 2016 (chairperson)
National Heart, Lung, and Blood Institute
NHLBI P30 Review (ARRA funds), 2009
NHLBI Special Emphasis Panel – Research Centers at Minority-Serving Institutions
Basic Research in Calcific Aortic Valve Disease (R01); April 4, 2012.
NHLBI P50 Review - RFA-NHLBI Research Centers at Minority Serving Institutions -
Phase II, December 2012

FY15 Peer Reviewed Medical Research Program (PRMRP) for the Department of Defense
Congressionally Directed Medical Research Programs: Peer review panel - Programs in
cardiovascular health, Fall 2015

Ad hoc peer review panel for the Department of Defense Congressionally Directed Medical
Research Programs (CDMRP), Peer Reviewed Medical Research Program (PRMRP), Focus
Program Award Mitochondria (FP-MTD), Fall 2020

Site Visits

2010 FAMRI Julius B. Richmond Center of Excellence at the American Academy of Pediatrics,
Elk Grove Village, Illinois

Core Director – UMMC Department of Pharmacology and Toxicology Histology Services, 2018-
present

Committees

Institutional Review Board (Human Studies Subcommittee) of the Central Texas
Veterans Health Care System, 2000 – 2006
Publications Committee, Council for High Blood Pressure Research (Ad Hoc),
2003 – 2006
Radioisotope Protocol Review Committee of the Central Texas Veterans Health Care
System, 2004 – 9/25/08
Subcommittee on Research Safety of the Central Texas Veterans Health Care System, 2004
– 2008; Chair, 10/1/06 – 9/25/08
Research and Development (R&D) Committee of the Central Texas Veterans Health Care
System, 2006 – 9/25/08
Public Affairs Committee (Alternate), The American Physiological Society, 2005 – 2006
Institutional Biosafety Committee (*Ex-Officio*), Texas A&M University, 2006 – June 2007
Institutional Biosafety Committee, Texas A&M University, June 2007 – 9/25/08
Admissions Committee for the Graduate Program in Pharmacology and Toxicology, The
University of Mississippi Medical Center, 2010 – 2012
Graduate Program Committee, Dept. Pharmacology, The University of Mississippi Medical
Center, 2012 – present
Faculty Search Committee, Department of Pharmacology and Toxicology, The University of

| | |
|-----------------------------|--|
| Senior Editor: 2009 – 2013 | Congestive Heart Failure |
| Section Editor: 2007 – 2013 | Congestive Heart Failure: Translational Research |
| Guest Editor: 2007 | Journal of Cardiovascular Pharmacology |
| | Review Series - <i>Novel Drugs Targeting Hypertension: Renin Inhibitors and Beyond</i> |
| 2010 | Journal of Cardiovascular Pharmacology |
| | Review Series - <i>Novel Drugs Targeting Hypertension: A Follow Up</i> |
| 2011 | Congestive Heart Failure |
| | Review Series - Mitochondria and Heart Failure |

Guest Editor (2019): Raffaele Altara, PhD and George W. Booz, PhD, Cardiac Microvascular Endothelium Contribution to Cardiac Myocyte Growth, Structure, and Contractile Function in Frontiers in Cardiovascular Medicine: Cardiovascular Genetics and Systems Medicine

Guest Editor (2020), Special issue “Therapeutic targets and pharmacological treatment of COVID-19”, European Journal of Pharmacology

Coeditor (with R. Altara) (2020), Special series in Frontiers in Cardiovascular Medicine, “Immunomodulatory Approaches in Cardiovascular Diseases” Fouad A. Zouein, Editor.

Editorial Boards:

| | |
|--------------|--|
| 2003-present | Hypertension |
| 2004-2013 | Journal of Cardiovascular Pharmacology |
| 2005-2013 | Congestive Heart Failure |
| 2008-2012 | Cardiovascular Research |
| 2014-present | Cardiovascular Research |
| 2013-2015 | European Journal of Pharmacology |
| 2015-present | Clinical Science |
| 2009-2020 | Free Radical Biology and Medicine |

Ad Hoc Reviewer

Hypertension, Journal of Molecular and Cellular Cardiology, Circulation, Journal of Clinical Investigation, Circulation Research, American Journal of Physiology: Heart and Circulatory Physiology, American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, Journal of Applied Physiology, Journal of Cardiovascular Pharmacology, Expert Opinion on Emerging Drugs, The International Journal of Biochemistry and Cell Biology, American Journal of Hypertension, Molecular and Cellular Biochemistry, Regulatory Peptides, Journal of the American College of Cardiology, Cardiovascular Research, Biochemical Pharmacology; Acta Pharmacologica Sinica, American journal of Pathology; Congestive Heart Failure; American Journal of Physiology: Cell Physiology; Physiological Genomics; American Journal of Physiology: Endocrinology and Metabolism; British Journal of Pharmacology; Endocrine; Clinical and Experimental Pharmacology and Physiology; Endocrinology; Free Radical Biology and Medicine; Apoptosis; Cardiovascular Drugs and Therapy; Experimental Cell Research; European Journal of Pharmacology; Phytotherapy Research; Experimental Gerontology; Experimental Lung Research; Circulation: Heart Failure; Journal of Cellular Physiology; Biomedical Materials; PLOS ONE; European Journal of Heart Failure; JAK STAT, Journal of the Saudi Heart Association; Pharmacological Research; BBA - Molecular Cell Research; Expert Opinion On Pharmacotherapy; Environmental Toxicology and Pharmacology.

| Journal | Number of Reviews (as of 9/7/18) |
|--|-------------------------------------|
| Hypertension | 291 |
| Cardiovascular Research | 209 |
| Journal of Cardiovascular Pharmacology* | 198 |
| Free Radical Biology and Medicine | 119 |
| European Journal of Pharmacology* | 60 |
| AJP – Heart and Circulatory Physiology | 49 |
| The International Journal of Biochemistry & Cell Biology | 48 |
| Journal of Molecular and Cellular Cardiology | 47 |
| Circulation | 30 |
| Clinical Science | 26 |
| Circulation Research | 10 |
| Journal of Applied Physiology | 8 |

*Does not include as editor

Hypertension - Proceedings of the Inter-American Society of Hypertension, 2003-2008

Hypertension - Proceedings of the Council for High Blood Pressure Research, 2003-2008

AHA Abstract Reviewer – Scientific Sessions 2004 - 2010

Abstract Reviewer –

- 16th Annual Meeting of the Society for Free Radical Biology and Medicine (SFRBM), 2009
- 17th Annual Meeting of the Society for Free Radical Biology and Medicine and Society for Free Radical Research International XV Biennial Meeting, 2010
- SFRBM's 18th Annual Meeting, 2011
- SFRBM's 19th Annual Meeting, 2012
- SFRBM's 20th Annual Meeting, 2013
- SFRBM's 21th Annual Meeting, 2014
- SFRBM's 22th Annual Meeting, 2015
- Joint Meeting of the European Society of Hypertension and International Society of Hypertension, 2014

PRESENTATIONS

- 1990 FASEB, *N-Carbobenzoxy-glycyl-L-phenylalaninamide Inhibits Both Basal and Contraction-Initiated 2-Deoxyglucose Uptake by Frog Muscle* (Seminar)
- 1992 FASEB, *Angiotensin II Binding Sites on Hepatocyte Nuclei* (Poster)
- 1993 Weis Center, *Role of PKC in the Mitogenic Effect of Angiotensin II on Rat Cardiac Fibroblasts* (Seminar)
- 1994 Weis Center, *Involvement of Protein Kinase C and Calcium in Angiotensin II-Induced Mitogenesis of Cardiac Fibroblasts* (Seminar)
- APS Conference, Signal Transduction and Gene Regulation, San Francisco, *Role of Protein Kinase C in Angiotensin II-Induced Mitogenesis of Neonatal Rat Cardiac Fibroblasts* (Poster)
- 1995 Weis Center, *Angiotensin II-Induced Cardiac Hypertrophy: A Role for the Type II Receptor?* (Seminar)
- Annual Fall Conference and Scientific Sessions of the Council for High Blood

- Pressure Research, *AT2 Receptor Blockade Augments Angiotensin II-Induced Cardiomyocyte Hypertrophy* (Seminar)
Dept. of Medical Pharmacology and Toxicology, Texas A&M University School of Medicine, *Role of Angiotensin II in Cardiac Hypertrophy and Remodeling* (Seminar)
- 1997 Dept. of Physiology, University of Florida, School of Medicine, *Opposing Roles of the Angiotensin II Receptor Subtypes in Cardiac Hypertrophy* (Seminar)
Weis Center, *Opposing Roles of the Angiotensin II Receptor Subtypes in Cardiac Hypertrophy* (Seminar)
College of Pharmacy, Division of Pharmacology and Experimental Therapeutics, University of Kentucky, *Opposing Roles of the Angiotensin II Receptor Subtypes in Cardiac Hypertrophy* (Seminar)
Children's Hospital Medical Center, Division of Pulmonary Medicine, Allergy, and Clinical Immunology, University of Cincinnati, *Opposing Roles of the Angiotensin II Receptor Subtypes in Cardiac Hypertrophy* (Seminar)
- 1998 H. Lee Moffitt Cancer Center and Research Institute, *Cardiac Actions of Angiotensin II* (Seminar)
- 2001 American College of Cardiology, Annual Scientific Session
Angiotensin II modulates gp130 signaling in cardiac myocytes by tyrosine phosphatase activation (Poster).
- 2001 Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, *Endothelin-1 inhibits activation of the LIF receptor in cardiomyocytes* (Poster).
- 2003 AHA Scientific Conference on Molecular Mechanisms of Growth, Death and Regeneration in the Myocardium: Basic Biology and Insights into Ischemic Heart Disease and Heart Failure, *Role for β -arrestins, but not GRKs, in angiotensin II-induced internalization of AT₁* (Poster).
- 2004 American College of Cardiology, Annual Scientific Session
Rescue of Internalization-Impaired Angiotensin II AT1 Mutants by β -Arrestin Overexpression (Poster).
- 2004 Heart Failure Society of America, 8th Annual Scientific Meeting
Molecular Mechanisms of IL-6-Related-Cytokine STAT3 Regulation in Cardiac Myocytes (Poster).
- 2004 Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research
The Anti-Inflammatory Agent Parthenolide has Differential and Independent Effects on Jak-STAT and ERK Signaling in Cardiac Myocytes (Poster).
- 2004 American Society for Cell Biology
Interferon- γ has a Potent Cytostatic Effect via STAT1 Activation on the A549 Human Lung Cancer Cell Line (Poster)
- 2005 Heart Failure Society of America, 9th Annual Scientific Meeting
Parthenolide induces oxidative stress in cardiomyocytes: Differential activation of mitochondrial and NADPH oxidases (Poster).
- 2005 University of Mississippi Medical Center, Department of Physiology & Biophysics
Making the Best of IL-6-Type Cytokines in the Stressed Heart: From STAT3 to SOCS3 to ROS.
- 2007 XIX World Congress of the ISHR Bologna (Italy)
Oxidative stress blocks activation of JAK-STAT signaling in cardiac myocytes (Poster).
- 2007 Department of Cell & Developmental Biology and Anatomy, School of Medicine

- University of South Carolina
JAK-STAT Signaling in the Heart – Novel Insights into Regulation
- 2007 The 6th Annual Symposium: The Cutting Edge – Cardiology for the Future, Long Beach Memorial Medical Center, Long Beach, California
PARP Inhibitors in Heart Failure: Translational Medicine in Progress
- 2008 University of Mississippi Medical Center, Department of Pharmacology and Toxicology
JAK-STAT Signaling in the Injured and Failing Heart
- 2008 TTUHSC School of Pharmacy, Department of Pharmaceutical Sciences
JAK-STAT Signaling in the Injured and Failing Heart
- 2009 University of Mississippi Medical Center, SURE Seminar, *Mending a Broken Heart: New Approaches to Heart Failure Prevention or Reversal*
- 2010 University of Mississippi Medical Center, Department of Physiology and Biophysics, *Hydrogels as a Platform for Stem Cell Delivery to the Heart*
- 2010 University of Mississippi Medical Center, Department of Pharmacology and Toxicology, *Can the protective actions of JAK-STAT in the heart be exploited therapeutically?*
- 2010 University of Mississippi Medical Center, Department of Biochemistry, *Uncovering the Versatility of STAT3 in Endothelial Cells.*
- 2011 University of Mississippi Medical Center, Department of Pharmacology and Toxicology, Work In Progress 2011: Understanding JAK-STAT in the Heart
- 2012 Department of Pharmacology, University of Mississippi School of Pharmacy, *Redox-Sensitivity of STAT3: Implications for Heart Failure*
- 2012 University of Mississippi Medical Center, Department of Pharmacology and Toxicology, *Redox-Sensitivity of STAT3: Implications for Heart Failure*
- 2012 Division of Cardiology, Department of Medicine, The Johns Hopkins University, *Redox-Sensitivity of STAT3: Implications for Heart Failure*
- 2018 Mini-symposium on the role of inflammation in heart failure, Center for Heart Failure Research at the Oslo University
- 2019 University of Mississippi Medical Center, Department of Pharmacology and Toxicology, *Novel aspects of cardiac remodeling*

By members of the lab:

- 2004 CHEST (American College of Chest Physicians)
Activation of STAT1 BY IFN- γ Inhibits Growth of Human Non-Small Cell Lung Cancer Cells (Poster).
- 2005 CHEST (American College of Chest Physicians)
Role of STAT1 in the Permissive Effect of Interferon- γ on FAS-Induced Apoptosis of Non-Small Cell Lung Cancer Cells
- 2005 *XXVIIth Annual Meeting of the North American Section of the International Society for Heart Research New Orleans, LA May 12 - 15, 2005 "Cardiovascular Disease and Health". Anti-inflammatory parthenolide inhibits JAK1 activation in cardiac myocytes but induces oxidative stress* (Poster).
- 2006 ATS International Conference in San Diego, California, May 19th-24th. *Role for STAT3 in Apoptosis Signaling by Interferon- γ in Human Nonsmall Cell Lung Cancer A549 Cells* (Poster).
- 2010 High Blood Pressure Research 2010 Scientific Sessions, Washington D.C. *Nitroxyl activates redox-sensitive stress signaling in endothelial cells and has anti-inflammatory actions* (Poster; Carlos Zgheib).

- 2010 High Blood Pressure Research 2010 Scientific Sessions, Washington D.C. PP2A plays a critical role determining the endothelial cell gene expression profile of leukemia inhibitory factor (LIF). (Oral; Carlos Zgheib).
- 2010 ASCB 50th Annual Meeting, Philadelphia, PA. Sodium Selenate Enhances Endothelial Cell STAT3 Tyrosine Phosphorylation and DNA Binding. (Poster; Hani Alturkmani/ Carlos Zgheib).
- 2011 EB2011, Washington, DC. Transient Receptor Potential Type C Channels Play a Critical Role in Angiogenesis (Poster; Fouad Zouein).
- 2012 EB2012, San Diego, CA, DUAL ROLE OF STAT3 IN HYPERTENSION-INDUCED CARDIAC REMODELING (Poster; Fouad Zouein).
- 2012 CHBPR 2012, Washington, DC. STAT3 Affects Myofibrillar Structure and Its Loss May Contribute to Heart Failure in Hypertension (Oral; Fouad Zouein).
- 2012 CHBPR 2012, Washington, DC. Acyloxy Nitroso Compounds Inhibit LIF Signaling in Endothelial Cells and Cardiac Myocytes: Evidence That STAT3 Signaling is Redox-Sensitive. (Poster; Carlos Zgheib).
- 2013 CHBPR 2013, New Orleans, LA. Role of STAT3 in Collagen Deposition and Organization in the Normal and Hypertensive Heart (Poster; Fouad Zouein).
- 2015 AHA's Council on Hypertension 2015 Scientific Sessions conference in Washington, D.C. Importance of the C-Terminal Transactivation Domain of STAT3 in Hypertension-Induced Cardiac Hypertrophy (Oral; Fouad Zouein).

HONORS AND AWARDS

- 1972 - 1976 Dean's List, St. Joseph's University
1972 - 1976 Presidential Scholarship, St. Joseph's University
1977 - 1980 National Research Service Award
University of Pennsylvania
- 1983 - 1986 Dean's List, Drexel University
1986 - 1987 Foerderer Fellow, Thomas Jefferson University
1988 Summer Fellowship
American Heart Association, Maine Chapter
- 1988 - 1989 Speck Fellowship, Thomas Jefferson University
1988 & 1977 Student Scholarship
Mt. Desert Island Biological Laboratory
- 1989 - 1990 University Fellowship
Thomas Jefferson University
- 1990 Fellowship
Mt. Desert Island Biological Laboratory
- 1990 Elected Member
Mt. Desert Island Biological Laboratory
- 2003 Editorial Board, Hypertension
2004 Top Ten Hypertension Reviewer
2004 Fellow of the American Heart Association/American Stroke Association
- 2004 Editorial Board, Journal of Cardiovascular Pharmacology
2005 – 2006 Adjunct Assistant Professor of Biology, Mary Hardin Baylor

University
2005 Editorial Board, Congestive Heart Failure
2008 Consulting Editor/Editorial Board, Cardiovascular Research
2009 Editorial Board, Free Radical Biology and Medicine
2009 Excellence in Research Award at the University of Mississippi
Medical Center, Bronze Level
2010 Excellence in Research Award at the University of Mississippi
Medical Center, Gold Level
2011 Cardiovascular Research, Certificate of Appreciation (100
manuscripts)
2012 Hypertension, Certificate of appreciation as a top reviewer
2013 F1000Prime Faculty Member (Cardiovascular Pharmacology)
2013 Hypertension, Certificate of appreciation as top reviewer
2013 HBPR 2013, Co-chair of session: Cardiac Hypertrophy and
Dysfunction
2013 Editorial Board, European Journal of Pharmacology
2014 Editorial Board, Cardiovascular Research
2014 Top Ten Hypertension Reviewer
2017 Top Hypertension Reviewer
2018 Top Hypertension Reviewer
2018 A Top Reviewer, Cardiovascular Research

As Mentor

2004 Nikhat Salamat, M.D., Best Lung Cancer Poster, CHEST Meeting
2005 Christopher Spradley, M.D., Young Investigator Award, CHEST
Meeting
2005 Mazen Kurdi, Ph.D., Young Investigator Best Oral Presentation,
1st Annual Retreat of the Texas A&M University System Health
Science Center Cardiovascular Research Institute
2009 Joshua Burkhart, M1 Medical Student, Recipient: Dean's Summer
Medical Research Fellowship
2010 Fouad Zouein, 1st year graduate student, poster award recipient:
Model system for investigating the role of transient receptor
potential type C channels in angiogenesis.
2011 Carlos Zgheib, 1st place poster at Research Day at the University
of Mississippi Medical Center: Zgheib C., Zouein F., Chidiac R.,
Kurdi M., Booz G.W. Calyculin A Reveals Serine/Threonine
Phosphatase PP1 as a Regulatory Nodal Point in Canonical
STAT3 Signaling of Human Microvascular Endothelial Cells.
2011 Fouad Zouein, AHA Scientific Sessions Travel Award–PVD
council workshop- Orlando, Florida
2012 Fouad Zouein, School of Health Related Professions Research
Day - 1st place award for outstanding research
2012 Fouad Zouein, recipient of a 2012 Research Mini-Fellowship from
the Society for Free Radical Biology and Medicine (SFRBM) for
his study entitled Cardiac Mitochondrial ROS Production
2013 Fouad Zouein. Junior Initiative Award from the European Cytokine
Society for his review article "LIF and the Heart: Just Another
Brick in the Wall?" Fouad A. Zouein, Mazen Kurdi, and George
W. Booz
2014 Fouad A. Zouein, Ph.D., Regions Graduate Research Award

2014 Venkata Ramana Vaka, recipient of a 2014 Research Mini-Fellowship from the Society for Free Radical Biology and Medicine (SFRBM)

COLLABORATIONS

Nazareno Paolucci, MD, PhD
Assistant Professor of Medicine
Division of Cardiology
Johns Hopkins University
2010 – 2015

Edward J. Lesnefsky, MD, FACC, FAHA
Division of Cardiology
Professor of Medicine and Biochemistry
Virginia Commonwealth University
Chief, Cardiology Section
McGuire Veterans Affairs Medical Center
Richmond, VA 23249
2014 – 2018

Raffaele Altara, Ph.D.
Post-Doctoral Researcher
Oslo University Hospital – Ullevål
Institute for Experimental Medical Research, University of Oslo
2017- present

William Louch, Ph.D.
Professor and Division Head, Core Facility for Advanced Light Microscopy
Oslo University Hospital – Ullevål
Institute for Experimental Medical Research, University of Oslo
2017- 2018

Alessandro Cataliotti, M.D., Ph.D.
Oslo University Hospital – Ullevål
Institute for Experimental Medical Research, University of Oslo
Institute for Experimental Medical Research, University of Oslo
2017- present

Fouad A. Zouein, Ph.D. FAHA
Assistant Professor
Department of Pharmacology and Toxicology
American University of Beirut & Medical Center
Faculty of Medicine
Riad El-Solh 1107 2020
Beirut-Lebanon
2015 - present

Mazen Kurdi, Ph.D.
Professor
Department of Chemistry and Biochemistry

The Lebanese University
2008 - present

Richard J. Roman, Ph.D., Professor
Fan Fan, M.D., M.S., Assistant Professor
Department of Pharmacology and Toxicology
The University of Mississippi Medical Center
2017 – present

Mark W. Cunningham Jr., Ph.D., MBA
Assistant Professor
Department of Pharmacology & Toxicology
University of Mississippi Medical Center
2017 – present

Roy J. Duhe, Ph.D.
Professor
Department of Pharmacology and Toxicology
The University of Mississippi Medical Center
2008 - 2017

Istvan Arany, Ph.D., C.Sc.
Professor of Pediatrics
Department of Pediatrics, Division of Pediatric Nephrology
University of Mississippi Medical Center
2010 - 2014

Kenneth Liechty, MD
Associate Professor of Pediatric Surgery
Department of Surgery
University of Mississippi Medical Center
2010 - 2012

TEACHING ACTIVITIES (classroom or teaching laboratory)

1974 Cell Physiology Laboratory, University of Pennsylvania Graduate Faculty
1989 Blood Bank Techniques Laboratory, Thomas Jefferson University

***The Texas A&M University System Health Science Center
Graduate Faculty and College of Medicine***

2003-2007 MPHY 606, Advanced Cardiovascular Biology: Signal Transduction in
Heart Failure
2003-2007 MSCI 601, Principles of Medical Science (Part 1): Biomembranes,
Membrane Transport
2003-2005 MSCI 689, Advanced Topics in Cell Signaling: G-Protein Receptor
Signaling,
Cytokine Receptor Signaling
2006 MSCI 612, Current Topics in Cell Signaling: G-Protein Receptor Signaling,
Cytokine Receptor Signaling
2004 MPHY 901, Medical Physiology: Adrenal Glands, Hypothalamus/Pituitary
Gland, Endocrine Pancreas, Thyroid Gland, Calcium and Phosphate
Metabolism

2004-2007 MSCI 602, Principles of Medical Science (Part 2): Thyroid, Endocrine
Pancreas, Adrenal Gland and Calcium Regulation
2004 S&W Fellows Course: Cytokines & Heart Failure

Course Director

2006 MSCI 612, Current Topics in Cell Signaling

University of Mississippi School of Medicine and School of Graduate Studies in the Health Sciences

Spring 2009 – present PH652: Advanced Topics in Pharmacology
Fall 2009 – present PH723: Mechanisms of Drug Action; Cardiovascular
Pharmacology (Three 2-hour lectures)
Fall 2009 – present PH620/722: Introduction To Pharmacology & Therapeutics
(Medical Pharmacology): Heart Failure, Vasodilators and
Rx of Angina Pectoris (Two 1-hour lectures)
Spring 2010 – present PH620/722: Autonomic Drug Responses Small Groups
PH626/726: Pharmacology (Dental)/Fundamental
Pharmacology: Cardiac Physiology Overview, Heart
Failure, Angina
Spring 2010 Pharm 790: Special Topics in Pharmacology and
Toxicology
(4 credits)
Spring 2016 – present PH724: Experimental Design & Methods: Mitochondria in
cell signaling; Approaches for their study, 3 hours
2017 – present 4th Year Pharm Medical Elective

Course Director

2014 – 2015 PH723: Mechanisms of Drug Action
2019 – present PH723: Mechanisms of Drug Action
2021 – present PH724: Experimental Design & Methods

OTHER TEACHING OR MENTORING ACTIVITIES

Scientific Partner, 2009 – present
The Master's Program in Cardiovascular Pharmacology
The Lebanese University
Beirut, Lebanon

Preclinical Advisor, 2013 – present
3-4 M1 and 3-4 M2 Students

Mark Cunningham, Ph.D.
2017 - 2018
Instructor, Department of pharmacology and Toxicology, UMMC
Collaborator member of mentoring team

Research Mentor - Pulmonary Fellows, Scott & White Hospital and Cardiovascular Research Institute, Texas A&M College of Medicine

| | |
|-------------|---|
| 2003 - 2005 | Nikhlat Salamat, M.D. <i>Role of STAT Transcription Factors in Apoptosis of Human Non-Small-Cell Lung Cancer Cells</i> |
| 2003 - 2005 | Christopher Spradley, M.D. <i>Antioncogenic Potential of GRIM-19 in Human Non-Small-Cell Lung Cancer Cells</i> |
| 2005 - 2006 | Gagan Prakash, M.D. <i>Regulation of Non-Small Cell Cancer Apoptosis by Interferon-γ</i> |

Post-Doctoral Fellows

| | |
|-------------|-------------------------|
| 2004 – 2008 | Mazen Kurdi, Ph.D. |
| 2009 – 2011 | Thomas Sebastian, Ph.D. |
| 2015 | Fouad A. Zouein, Ph.D. |
| 2015 – 2017 | Raffaele Altara, Ph.D. |

Technicians, Graduate Students, and Summer Students

| | | |
|-------------------------------------|-----------------------|---|
| 2000 – 2004 | Jonathan Day, B.Sc. | Technician I, II |
| 2003 – 2005 | J. Ryan Brewer, B.S. | Technician I |
| 2004 – 2005 | Jeremy Nickolai, B.S. | Technician 1 |
| 2003 | Kelly Culver | Summer Student |
| 5/04 – 1/05 | William White | College Student |
| 5/04 – 12/04 | Nathan Guthrie | College Student |
| 2004 (fall) | Samantha Bruce | Graduate Student (Rotation) |
| 6/28/07–8/31/07 & 8/1/08–9/18/08 | Carlos Zgheib | Masters Student, Holy Spirit University, Lebanon |
| 6/28/07–8/31/07 | Marita Faddoul | Masters Student, Holy Spirit University, Lebanon |
| 6/28/07–8/31/07 | Youssef Bou Assy | Masters Student, Holy Spirit University, Lebanon |
| 8/1/08–9/18/08 | Hovig Khachadourian | Undergraduate, Holy Spirit University, Lebanon |
| 1/1/09–7/10/09 | Marilyn Burke | Graduate Student, Dept. Pharmacology and Toxicology, University of Mississippi School of Medicine |
| Summer 2009 | Joshua Burkhart | M1 Medical Student, University of Mississippi School of Medicine <i>The role of SOCS3 in modulating IL-6 type cytokine signaling in mouse coronary endothelial cells</i> |
| Summer 2009 | Qianli (Lee) Tian | High School Student Summer Undergraduate Research Experience (SURE) participant <i>Isolating CD34⁺ Stem Cells from Umbilical Cord Blood for Cardiac</i> |

| | | |
|--|---------------------------------------|---|
| 7/2009–8/2010 | Fouad Zouein | <i>Repair</i> Research Technician II, University of Mississippi School of Medicine |
| Summer 2009 | Rony Chidiac | Masters Student, Holy Spirit University, Lebanon Summer Undergraduate Research <i>The Utility of Anti-Oxidant Hydrogels for Stem Cell Delivery to the Heart</i> |
| 8/2010–11/2013 | Fouad Zouein | Graduate Student: Medical Pharmacology, University of Mississippi School of Medicine |
| 08/2009–2012 | Carlos Zgheib | Graduate Student: Medical Pharmacology, University of Mississippi Medical Center |
| 7/8/10–9/23/10 | Hani Jamal Alturkmani | 3 rd year medical student Alfaisal University, College of Medicine |
| 7/1/11–9/23/11 | Hani Jamal Alturkmani | 4 th year medical student Alfaisal University, College of Medicine |
| | Nour Eddin F. Alshaaer | 3 rd year medical student Alfaisal University, College of Medicine |
| 6/1/12–8/15/12 | Charles Powell | SURE Student University of Mississippi |
| 9/1/11–8/30/12 | Kathryn Cooper | Technician I |
| 6/1/13–8/15/13 | Charles Powell | SURE Student University of Mississippi |
| 1/1/12–5/1/12 | Barak Gunter | Graduate Student, Medical Pharmacology/Psychiatry and Human Behavior |
| 5/5/13–9/15/13 & 5/13/14–9/1/15 | Venkata Ramana Vaka | Graduate Student: Medical Pharmacology, University of Mississippi Medical Center |
| Summer 2019 (with Dr. Mark Cunningham) | | |
| | Daniel Azubuike (SURE student) | |
| | Brett Bowling (medical student/MSRP) | |
| | Daniel Kennedy (medical student/MSRP) | |
| Summer 2020 | | |
| | Alex N. Smith (medical student/MSRP) | |
| | Daniel G. Thomas (medical student) | |

Ph.D. Thesis Advisor

Dr. Carlos Zgheib (2009-2012), *“Regulation of Inflammatory JAK-STAT Signaling: Implications For Cardiac Repair and Remodeling”*

Dr. Fouad Zouein (2010-2013), *“Importance of STAT3 in Hypertension-Induced Remodeling of the Heart”*

Thesis Committees

| | |
|---------------|--|
| 2007–2008 | Joana Dado, Masters The Graduate School of Biomedical Sciences The Texas A&M University System Health Science Center College of Medicine |
| 2009–2012 | Chetan Patil, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center |
| 2011–2012 | Carlos Zgheib, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center |
| 2012-2013 | Fouad A. Zouein, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center |
| 2013 | Kandis V. Backus, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center |
| 2014–2017 | Barak Gunter, Doctoral Student, Psychiatry and Human Behavior School of Graduate Studies in the Health Sciences University of Mississippi Medical Center |
| 2015–2018 | Xiaochen "Alex" He, Doctoral Student, Medical Pharmacology School of Graduate Studies in the Health Sciences University of Mississippi Medical Center |
| 2019 - 2020 | Shaoxun Wang, Doctoral Student, Experimental Therapeutics and Pharmacology, School of Graduate Studies in the Health Sciences University of Mississippi Medical Center |
| 2019 - | Letao Fan, Doctoral Student, Experimental Therapeutics and Pharmacology, School of Graduate Studies in the Health Sciences University of Mississippi Medical Center |
| 2019–2020 | Joshua R. Jefferson, master's degree in Health Sciences, Department of Health Sciences in the School of Health Related Professions, University of Mississippi Medical Center |
| 2020 (Oct 14) | Rana Ghali, Member of the Committee for Doctoral Degree Defense, Université de Paris |
| 2020 (Dec 14) | Maya Dia, Doctorante, IHU OPERA-CARDIOPROTECTION, Laboratoire CarMeN (Cardiovasculaire, Métabolisme, Diabétologie et Nutrition), Unité INSERM U1060/Université-Lyon1 |
| 2020 - | Owen Herrock, Doctoral Student, Experimental Therapeutics and Pharmacology, School of Graduate Studies in the Health Sciences University of Mississippi Medical Center |

TAMHSC Division of Molecular Cardiology Activities

2004 – 2005 Organizer and Chair, Heart and Lung Focus Group

The Texas A&M University System Health Science Center

2005 Judge, 10th Annual Health Science Center Research Symposium
2006 Poster Judge, 2nd Annual Cardiovascular Research Institute
Retreat
2007 Poster Judge, 3rd Annual Cardiovascular Research Institute Retreat

The University of Mississippi Medical Center

| | |
|-------------|---|
| 2009 | Poster Judge, Research Day, School of Graduate Studies in the Health Sciences |
| 2009 – 2014 | Grants In Progress, Department of Pharmacology and Toxicology |
| 2015 | Poster Judge, Research Day, School of Graduate Studies in the Health Sciences |

Current Status of Trainees

Postdoctoral Fellows:

Raffaele Altara, PhD

¹Post-Doctoral Researcher
Institute for Experimental Medical Research (IEMR)
Oslo University Hospital - Ullevål
Kirkeveien 166, Build.7, 4th floor
0450 Oslo, NO

²Faculty Scientist Educator
Department of Pathology
School of Medicine, University of Mississippi Medical Center
Jackson, 39216, MS, USA

Mazen Kurdi, PhD

Professor
Department of Chemistry and Biochemistry
Lebanese University
Faculty of Sciences, Section I
Rafic Hariri Educational Campus,
Hadat, Lebanon

Graduate Students:

Carlos Zgheib, PhD

Assistant Professor
University of Colorado Denver
Anschutz Medical Campus


Fouad A. Zouein, PhD

Assistant Professor
Department of Pharmacology and Toxicology
American University of Beirut
Beirut, Lebanon

PUBLICATIONS

My Bibliography: <https://www.ncbi.nlm.nih.gov/myncbi/1zEddPyfmx-/bibliography/public/>
Google Scholar: <https://scholar.google.com/citations?user=QfiysRoAAAAJ&hl=en&oi=ao>

| | All | Since 2016 |
|-----------|------|------------|
| Citations | 6122 | 2540 |
| h-index | 40 | 27 |
| i10-index | 80 | 61 |



Research Articles

1. Pritchard JB, **Booz G**, Kleinzeller A. Renal sugar transport in the winter flounder. V. Secretion of 2-deoxy-D-galactose. *Am. J. Physiol.* 234: F424-431, 1978.
2. Pritchard JB, **Booz G**, Kleinzeller A. Renal sugar transport in the winter flounder. VI. Reabsorption of D-mannose. *Am. J. Physiol.* 242: F415-422, 1982.
3. Kleinzeller A, Forrest JN, Cha C-J, Goldstein J, **Booz G**. Cell solute composition and potassium effects in slices of the rectal gland of the dogfish shark (*Squalus acanthias*). *J. Comp. Physiol.* 155B: 145-153, 1985.
4. Ziyadeh FN, Feldman GM, **Booz GW**, Kleinzeller A. Taurine and cell volume maintenance in the shark rectal gland: Cellular fluxes and kinetics. *Biochim. Biophys. Acta* 943: 43-52, 1988.
5. Feldman GM, Ziyadeh FN, Mills JW, **Booz GW**, Kleinzeller A. Propionate induces cell swelling and K⁺ accumulation in shark rectal gland. *Am. J. Physiol.* 257: C377-C384, 1989.
6. Kleinzeller A, **Booz GW**, Mills JW, Ziyadeh FN. pCMBs-induced swelling of dogfish (*Squalus acanthias*) rectal gland cells: Role of the Na⁺,K⁺-ATPase and the cytoskeleton. *Biochim. Biophys. Acta* 1025: 21-31, 1990.
7. **Booz GW**, Conrad KM, Hess AL, Singer HA, Baker KM. Angiotensin II binding sites on hepatocyte nuclei. *Endocrinology* 130:3641-3649, 1992.
8. **Booz GW**, Bianchi CP. Stimulation-enhanced 3-O-methylglucose efflux from the frog sartorius: Kinetics and properties of the system. *Biochim. Biophys. Acta* 1109: 132-140, 1992.
9. **Booz GW**, Bianchi CP. 2-Deoxyglucose transport by the frog sartorius: Effects of electrical stimulation and N-carbobenzoxy-glycyl-L-phenylalaninamide. *Comp. Biochem. Physiol.* 106A: 471-477, 1993.
10. Schorb W, **Booz GW**, Dostal DE, Conrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. *Circ. Res.* 72: 1245-1254, 1993.
11. **Booz GW**, Dostal DE, Singer HA, Baker KM. Involvement of protein kinase C and Ca²⁺ in angiotensin II-induced mitogenesis of cardiac fibroblasts. *Am. J. Physiol.* 267: C1308-C1318, 1994.
12. **Booz GW**, Taher M, Baker KM, Singer HA. Angiotensin II-induces phosphatidic acid formation in neonatal rat cardiac fibroblasts: Evaluation of the roles of phospholipases C and D. *Mol. Cell. Biochem.* 141: 135-143, 1994.
13. **Booz GW**, Baker KM. Protein kinase C in angiotensin II signalling in cardiac fibroblasts: Role in the mitogenic response. *Ann. N.Y. Acad. Sci.* 752: 158-167, 1995.
14. Thomas WG, Baker KM, **Booz GW**, Thekkumkara TJ. Evidence against a role for protein kinase C in the regulation of the angiotensin II (AT_{1A}) receptor. *Eur. J. Pharmacol.* 295: 119-122, 1996.

15. **Booz GW**, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. *Hypertension* 28: 635-640, 1996.
16. **Booz GW**, Carl LL, Baker KM. Amplification of angiotensin II signaling in cardiac myocytes by adenovirus-mediated overexpression of the AT1 receptor. *Ann. N.Y. Acad. Sci.* 874: 20-26, 1999.
17. **Booz GW**, Dostal DE, Baker KM. Paracrine actions of cardiac fibroblasts on cardiomyocytes: Implications for the cardiac renin-angiotensin system. *Am. J. Cardiol.* 83:44H-47H, 1999.
18. Dostal DE, **Booz GW**, Baker KM. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and β -adrenergic stimulation. *Basic Res. Cardiol.* 95: 485-491, 2000.
19. Fukuzawa J, **Booz GW**, Hunt RA, Shimizu N, Karoor V, Baker KM, Dostal DE. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. *Hypertension* 35: 1191-1196, 2000.
20. **Booz GW**, Day JNE, Speth R, Baker KM. Cytokine G-protein signaling crosstalk in cardiomyocytes: attenuation of Jak-STAT activation by endothelin-1. *Mol. Cell. Biochem.* 240:39-46, 2002.
21. **Booz GW**, Day NE, Baker KM. Angiotensin II effects on STAT3 phosphorylation in cardiomyocytes: Evidence for Erk-dependent Tyr705 dephosphorylation. *Basic Res. Cardiol.* 98: 33-38, 2003.
22. Steinle JJ, **Booz GW**, Meininger CJ, Day JNE, Granger HJ. β_3 -Adrenergic receptors regulate retinal endothelial cell migration and proliferation. *J. Biol. Chem.* 278: 20681-20686, 2003.
23. Kule CE, Karoor V, Day JNE, Thomas WG, Baker KM, Acker KA, **Booz GW**. Agonist-dependent internalization of the angiotensin II type one receptor (AT₁): Role of C-terminus phosphorylation in recruitment of β -arrestins. *Reg. Peptides* 120: 141-148, 2004
24. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, **Booz GW**, Dostal DE, Kumar R. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. *Reg. Peptides* 120: 5-13, 2004.
25. Kurdi M, **Booz GW**. Evidence that IL-6-Type Cytokine Signaling in Cardiomyocytes is Inhibited by Oxidative Stress: Parthenolide Targets JAK1 Activation by Generating ROS. *J. Cell. Physiol.* 212: 424-431, 2007
26. Kurdi M, **Booz GW**. Jak1 inhibition, but not STAT1 knockdown, blocks the synergistic IFN γ - and Fas-Induced apoptosis of human non-small cell lung cancer A549 cells. *J. Interferon Cytokine Res.* 27: 16-24, 2007.
27. Kurdi M, Bowers MC, Dado J, **Booz GW**. Parthenolide induces a distinct pattern of oxidative stress in cardiac myocytes. *Free Radic Biol Med.* 42: 474-481, 2007.
28. Kurdi M, Sivakumaran V, Duhé RJ, Aon MA, Paolucci N, **Booz GW**. Depletion of Cellular Glutathione Modulates LIF-Induced JAK1-STAT3 Signaling in Cardiac Myocytes. *Int J Biochem Cell Biol.* 2012;44:2106-15.
29. Arany I, Reed DK, Grifoni SC, Chandrashekar K, **Booz GW**, Juncos LA. A novel U-STAT3-dependent mechanism mediates the deleterious effects of chronic nicotine exposure on renal injury. *Am J Physiol Renal Physiol* 2012;302:F722-9.
30. Zgheib C, Zouein FA, Chidiac R, Kurdi M, **Booz GW**. Calyculin A Reveals Serine/Threonine Phosphatase PP1 as a Regulatory Nodal Point in Canonical STAT3 Signaling of Human Microvascular Endothelial Cells *J. Interferon Cytokine Res.* 2012;32:87-94
31. Smith JK, Patil CN, Patlolla S, Gunter BW, **Booz GW**, Duhé RJ. Identification of a redox-sensitive switch within the JAK2 catalytic domain. *Free Radic Biol Med* 2012;52:1101-10.
32. Alturkmani HJ, Zgheib C, Zouein FA, Alshaaer NEF, Kurdi M, **Booz GW**. Selenate Enhances STAT3 Transcriptional Activity in Endothelial Cells: Differential Actions of

- Selenate and Selenite on LIF Cytokine Signaling and Cell Viability *J Inorg Biochem.* 2012;109:9-15.
33. Zgheib C, Kurdi M, Zouein FA, Gunter BW, Stanley BA, Zgheib J, Romero DG, King SB, Paolucci N, **Booz GW**. Acyloxy Nitroso Compounds Inhibit LIF Signaling in Endothelial Cells and Cardiac Myocytes: Evidence that STAT3 Signaling is Redox-Sensitive. *PLoS One.* 2012;7:e43313.
 34. Zgheib C, Zouein FA, Kurdi M, **Booz GW**. Chronic treatment of mice with leukemia inhibitory factor does not induce cardiac remodeling but improves heart function. *Eur Cytokine Netw.* 2012;23:191-7.
 35. Zouein FA, Zgheib C, Hamza S, Fuseler JW, Hall JE, Soljancic A, Lopez-Ruiz A, Kurdi M, **Booz GW**. Protective Role of STAT3 in Early-Stage Hypertension-Induced Cardiac Remodeling Revealed by Mice Lacking STAT3 Serine 727 Phosphorylation. *Hyper Res* 2013;36:496-503.
 36. Werner T, Dombrowski S, Zgheib C, Zouein FA, Keen HL, Kurdi M, **Booz GW**. Elucidating functional context within microarray data by integrated transcription factor focused gene-interaction and regulatory network analysis. *Eur Cytokine Netw* 2013;24:75-90.
 37. Zouein FA, Duhé RJ, Arrany I, Shirey K, Hosler JP, Liu H, Saad I, Kurdi M, **Booz GW**. Loss of STAT3 in mouse embryonic fibroblasts reveals its janus-like actions on mitochondrial function and cell viability. *Cytokine* 2014;66:7-16.
 38. Zouein FA, Kurdi M, **Booz GW**, Fuseler JW. Applying Fractal Dimension and Image Analysis to Quantify Fibrotic Collagen Deposition and Organization in the Normal and Hypertensive Heart. *Microsc Microanal* 2014;20:1134-1144.
 39. Zeng H, Vaka R, He X, **Booz GW**, Chen JX. High Fat Diet Induces Cardiac Remodeling and Dysfunction: Assessment of the Role Played by SIRT3 Loss. *J Cell Mol Med.* 2015;19:1847-1856.
 40. Altara R, Manca M, Hessel MH, Gu Y, van Vark LJ, Akkerhuis M, Staessen JA, Struijker-Boudier HAJ, **Booz GW**, Blankesteyn WM. CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study. *J Cardiovasc Transl Res.* 2016;9:302-14. doi: 10.1007/s12265-016-9703-3. PubMed PMID: 27271043.
 41. Altara R, Harmancey R, Didion SP, **Booz GW**, Zouein FA. Cardiac STAT3 Deficiency Impairs Contractility and Metabolic Homeostasis in Hypertension. *Front Pharmacol.* 2016;7:436. PubMed PMID: 27899891; PubMed Central PMCID: PMC5110511.
 42. Altara R, Zouein FA, Bajestani SN, Cataliotti A, **Booz GW**. *In Silico* Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction. *Front Cardiovasc Med.* 2018 Feb 21;5:11. doi: 10.3389/fcvm.2018.00011. eCollection 2018. PubMed PMID: 29556499; PubMed Central PMCID: PMC5850854.
 43. Kaplan A, Yabluchanskiy A, Ghali R, Altara R, **Booz GW**, Zouein FA. Cerebral Blood Flow Alteration Following Acute Myocardial Infarction in Mice. *Biosci Rep.* 2018;38. pii: BSR20180382 doi: 10.1042/BSR20180382. PubMed PMID: 30061176.
 44. Harhous Z, Badawi S, Bona NG, Pillot B, Augeul L, Paillard M, **Booz GW**, Canet-Soulas E, Ovize M, Kurdi M, Bidaux G. Critical appraisal of STAT3 pattern in adult cardiomyocytes. *J Mol Cell Cardiol.* 2019 Jun;131:91-100. PMID: 31022374.
 45. Altara R, da Silva GJJ, Frisk M, Spelta F, Zouein FA, Louch WE, **Booz GW**, Cataliotti A. Cardioprotective effects of the novel compound Vastiras in a preclinical model of end-organ damage. *Hypertension* 2020;75(5):1195-1204. doi: 10.1161/HYPERTENSIONAHA.120.14704. PMID: 32200677.
 46. Kaplan A, Abidi E, Habeichi NJ, Ghali R, Alawasi H, Fakih C, Zibara K, Kobeissy F, Husari A, **Booz GW**, Zouein FA. Gender-biased kidney damage in mice following exposure to

- tobacco cigarette smoke: More protection in premenopausal females. *Physiol Rep.* 2020 Jan;8(2):e14339. doi: 10.14814/phy2.14339. PubMed PMID: 31981316; PubMed Central PMCID: PMC6981307.
47. Guo Y, Wang S, Liu Y, Fan L, **Booz GW**, Roman RJ, Chen Z, Fan F. Accelerated cerebral vascular injury in diabetes is associated with vascular smooth muscle cell dysfunction. *Geroscience* 2020. Mar 12. doi: 10.1007/s11357-020-00179-z.
 48. Fan F, Geurts AM, Pabbidi MR, Ge Y, Zhang C, Wang S, Liu Y, Gao W, Guo Y, Li L, He X, Lv W, Muroya Y, Hirata T, Prokop J, **Booz GW**, Jacob HJ, Roman RJ. A Mutation in γ -Adducin Impairs Autoregulation of Renal Blood Flow and Promotes the Development of Kidney Disease. *J Am Soc Nephrol.* 2020 Apr;31(4):687-700. doi: 10.1681/ASN.2019080784. Epub 2020 Feb 6. PubMed PMID: 32029431.
 49. Ghali R, Habeichi NJ, Kaplan A, Tannous C, Abidi E, Bekdash A, Farhat R, Itani H, Jurjus A, **Booz GW**, Mallat Z, Zouein FA. IL-33 Induces Type-2-Cytokine Phenotype but Exacerbates Adverse Cardiac Remodeling Post-Myocardial-Infarction with Eosinophil Recruitment, Worsened Systolic Dysfunction, and Ventricular Wall Rupture. *Clin Sci (Lond).* 2020;134(11):1191-1218. PMID: 32432676.
 50. Habeichi NJ, Mroueh A, Kaplan A, Ghali R, Al-Awassi H, Tannous C, Husari A, Jurjus A, Altara R, **Booz GW**, El-Yazbi A, Zouein FA. Sex-Based Differences in Myocardial Infarction-Induced Kidney Damage Following Cigarette Smoking Exposure: More Renal Protection in Premenopausal Female Mice. *Biosci Rep.* 2020;40(6):BSR20193229. PMID: 32519752.
 51. Kaplan A, Altara R, Manca M, Gunes HM, Cataliotti A, **Booz GW**, Zouein FA. Distorted Assessment of Left Atrial Size by Echocardiography in Patients with Increased Aortic Root Diameter. *Front Cardiovasc Med.* 2020. (Under Review).
 52. Duncan JW, Azubuiké D, **Booz GW**, Fisher B, Williams JM, Fan F, Ibrahim T, LaMarca B, Cunningham Jr MW. Angiotensin II Type 1 Receptor Autoantibody Blockade Improves Cerebral Blood Flow Autoregulation, Markers of Neuroprotection, and Hypertension in a Preclinical Model of Preeclampsia. *Hypertens Pregnancy.* 2020 2020 Oct 29:1-10. doi: 10.1080/10641955.2020.1833215. PMID: 33119997.
 53. **Booz GW**, Kennedy D, Bowling M, Robinson T, Azubuiké D, Fisher B, Brooks K, Chinthakuntla P, Hoang NH, Hosler JP, Cunningham Jr MW. Angiotensin II Type 1 Receptor Agonistic Autoantibody Blockade Improves Postpartum Hypertension and Cardiac Mitochondrial Function in Rat Model of Preeclampsia. *Biol Sex Differ.* 2021 (In Press)
 54. Travis OK, Tardo GA, Giachelli C, Siddiq S, Nguyen HT, Crosby MT, Johnson TD, Brown AK, **Booz GW**, Smith AN, Williams JM, Cornelius DC. Interferon γ neutralization reduces blood pressure, uterine artery resistance index, and placental oxidative stress in placental ischemic rats. *Am J Physiol Regul Integr Comp Physiol.* 2021 Aug 1;321(2):R112-R124. doi: 10.1152/ajpregu.00349.2020. Epub 2021 Jun 2. PMID: 34075808; PMCID: PMC8409917.
 55. Kaplan A, Altara R, Manca M, Gunes HM, Cataliotti A, **Booz GW**, Zouein FA. Distorted assessment of left atrial size by echocardiography in patients with increased aortic root diameter. *Egypt Heart J.* 2021 Jun 26;73(1):55. doi:10.1186/s43044-021-00177-2. PMID: 34173898; PMCID: PMC8236014.

Review Articles

1. Baker KM, **Booz GW**, Dostal DE. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. *Ann. Rev. Physiol.* 54: 227-241, 1992.
2. **Booz GW**, Dostal DE, Baker KM. Regulation of cardiac second messengers by angiotensins. In: *Cardiac Renin-Angiotensin System* (1st ed), edited by K. Lindpaintner and D. Ganten. New York: Futura Medical Publishers, 1994, p. 101-124.

3. Dostal DE, **Booz GW**, Baker KM. Cellular and subcellular localization of elements of the cardiac renin-angiotensin system. In: *Cardiac Renin-Angiotensin System* (1st ed), edited by K. Lindpaintner and D. Ganten. New York: Futura Medical Publishers, 1994, p. 1-21.
4. **Booz GW**, Baker KM. Molecular signalling mechanisms controlling the growth and function of cardiac fibroblasts. *Cardiovasc. Res.* 30: 537-543, 1995.
5. Dostal DE, **Booz GW**, Baker KM. Angiotensin II signalling pathways in cardiac fibroblasts: Conventional versus novel mechanisms in mediating cardiac growth and function. *Mol. Cell. Biochem.* 157: 15-21, 1996.
6. **Booz GW**, Baker KM. Role of the renin-angiotensin system in the pathophysiology of cardiac remodeling. *Blood Pressure* 5 (Suppl 2): 10-18, 1996.
7. **Booz GW**, Baker KM. Actions of angiotensin II on isolated cardiac myocytes. *Heart Failure Reviews* 3: 125-130, 1998.
8. **Booz GW**, Fukuzawa J, Dostal DE, Baker KM. Angiotensin and cytokine receptor crosstalk in modulation of cardiomyocyte hypertrophy. *Heart* 33:174-179, 2001.
9. **Booz GW**, Day JNE, Baker KM. Interplay between the cardiac renin angiotensin system and JAK-STAT Signaling: Role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. *J. Mol. Cell. Cardiol.* 34:1443-1453, 2002.
10. **Booz GW**. Putting the Brakes on Cardiac Hypertrophy: Exploiting the Intrinsic NO-cGMP Counter-Regulatory System. *Hypertension* 45: 341-346, 2005.
11. Kurdi M, De Mello WC, **Booz GW**. Working outside the system: An update on the unconventional behavior of the renin-angiotensin system components. *Int. J. Biochem. Cell Biol.* 37:1357-1367, 2005.
12. Kurdi M, **Booz GW**. Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of IL-6-type cytokine signaling. *J. Cardiovasc. Pharmacol.* 50: 126-141, 2007.
13. **Booz GW**. PARP Inhibitors and Heart Failure: Translational medicine caught in the act. *Congest. Heart Fail.* 13:105-12, 2007.
14. Kurdi M, **Booz GW**. G-CSF-Based Stem Cell Therapy for the Heart – *Unresolved Issues*. Part A: Paracrine Actions, Mobilization, Delivery. *Congest. Heart Fail.* 13: 221-227, 2007.
15. Kurdi M, **Booz GW**. G-CSF-Based Stem Cell Therapy – *Unresolved Issues*. Part B. *Congest. Heart Fail.* 2007;13:347-51
16. Kurdi M, **Booz GW**. JAK redux – A second look at the regulation and role of JAK kinases in the heart. *Am J Physiol Heart Circ Physiol* 2009;297:H1545-56.
17. Kurdi M, Chidiac R, Hoemann C, Zouein F, Zgheib C, **Booz GW**. Hydrogels as a platform for stem cell delivery to the heart. *Congest Heart Failure.* 2010;16(3):132-135.
18. Kurdi M, **Booz GW**. Deciphering STAT3 Signaling In the Heart: Plasticity and Vascular Inflammation. *Congest Heart Failure.* 2010;16:234-238
19. **Booz GW**. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. *Free Radic Biol Med* 2011;51:1054–1061.
20. Kurdi M, **Booz GW**. New Take on the Role of Angiotensin II in Cardiac Hypertrophy and Fibrosis. *Hypertension* 2011;57:1034-8.
21. Kurdi M, **Booz GW**. Three 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDAC. *J Mol Cell Cardiol* 2011;50:964-71.
22. Zouein FA, Duhe RJ, **Booz GW**. JAKs go nuclear: Emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. *Growth Factors* 2011;29:245-52
23. Zgheib C, Zouein FA, Kurdi M, **Booz GW**. Differential STAT3 Signaling in the Heart: Impact of Concurrent Signals and Oxidative Stress. *JAK-STAT* 2012;1:102-111.
24. Zouein FA, Zgheib C, Liechty KW, **Booz GW**. Post-Infarct biomaterials, left ventricular

- remodeling, and heart failure: Is good good enough? *Congest Heart Failure* 2012;18:284-90.
25. Zouein FA, Kurdi M, **Booz GW**. LIF and the Heart: Just Another Brick in the Wall? *Eur Cytokine Netw.* 2013;24:11-9.
 26. Zouein FA, Kurdi M, **Booz GW**. Dancing rhinos in stilettos: The amazing saga of the genomic and nongenomic actions of STAT3 in the heart. *JAK-STAT* 2013; 2:e24352.
 27. Zouein FZ, de Castro Brás LE, da Costa DV, Lindsey ML, Kurdi M, **Booz GW**. Heart Failure with Preserved Ejection Fraction: Emerging Drug Strategies. *J Cardiovasc Pharmacol* 2013;62:13-21.
 28. Zouein FA, **Booz GW**. AAV-Mediated Gene Therapy Cure for Heart Failure: Enhancing Contractility and Calcium Handling. *F1000* 2013;5:27.
 29. Altara R, Manca M, Sabra R, Eid AA, **Booz GW**, Zouein FA. Temporal cardiac remodeling post-myocardial infarction: dynamics and prognostic implications in personalized medicine. *Heart Fail Rev.* 2016 Jan;21(1):25-47. doi:10.1007/s10741-015-9513-8. PubMed PMID: 26498937.
 30. Zouein FA, Altara R, Chen Q, Lesnefsky EJ, Kurdi M and **Booz GW**. Pivotal Importance of STAT3 in Protecting the Heart from Acute and Chronic Stress: New Advancement and Unresolved Issues. *Front Cardiovasc Med* 2015 Nov 30;2:36. doi:10.3389/fcvm.2015.00036. eCollection 2015. Review. PubMed PMID: 2666490
 31. Altara R, Manca M, Brandão RD, Zeidan A, **Booz GW**, Zouein FA. Emerging Importance of Chemokine Receptor CXCR3 and Its Ligands in Cardiovascular Diseases. *Clin Sci (Lond).* 2016 Apr 1;130(7):463-78. doi: 10.1042/CS20150666.Review. PubMed PMID: 26888559.
 32. Fan F, Ge Y, Lv W, Elliott MR, Muroya Y, Hirata T, **Booz GW**, Roman RJ. Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology. *Front Biosci (Landmark Ed).* 2016;21:1427-1463. PMID: 27100515.
 33. Altara R, Mallat Z, **Booz GW**, Zouein FA. The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart. *J Immunol Res.* 2016;2016:4396368. PubMed PMID: 27795961; PubMed Central PMCID: PMC5066021.
 34. Kaplan A, Altara R, Eid A, **Booz GW**, Zouein FA. Update on the Protective Role of Regulatory T Cells in Myocardial Infarction: A Promising Therapy to Repair the Heart. *J Cardiovasc Pharmacol.* 2016;68:401-413. PubMed PMID: 27941502.
 35. Altara R, Giordano M, Nordén ES, Cataliotti A, Kurdi M, Bajestani SN, **Booz GW**. Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. *Front Endocrinol (Lausanne).* 2017 Jul 17;8:160. doi: 10.3389/fendo.2017.00160. eCollection 2017. Review. PubMed PMID: 28769873; PubMed Central PMCID: PMC5512012.
 36. Kaplan A, Abidi E, Ghali R, **Booz GW**, Kobeissy F, Zouein FA. Functional, Cellular, and Molecular Remodeling of the Heart under Influence of Oxidative Cigarette Tobacco Smoke. *Oxid Med Cell Longev.* 2017;2017:3759186. doi: 10.1155/2017/3759186. Epub 2017 Jul 20. Review. PubMed PMID: 28808498; PubMed Central PMCID: PMC5541812.
 37. Lv W, Fan F, Wang Y, Gonzalez-Fernandez E, Wang C, Yang L, **Booz GW**, Roman RJ. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. *Physiol Genomics.* 2018 Jan 1;50(1):20-34. doi: 10.1152/physiolgenomics.00039.2017. [Epub ahead of print] PubMed PMID: 29127220.
 38. Shekhar S, Cunningham MW, Pabbidi MR, Wang S, **Booz GW**, Fan F. Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches. *Eur J Pharmacol.* 2018 Aug 15;833:531-544. doi: 10.1016/j.ejphar.2018.06.028. Epub 2018 Jun 20. PubMed PMID: 29935175; PubMed Central PMCID: PMC6090562.

39. Zhang C, **Booz GW**, Yu Q, He X, Wang S, Fan F. Conflicting roles of 20-HETE in hypertension and renal end organ damage. *Eur J Pharmacol.* 2018 Aug 15;833:190-200. doi: 10.1016/j.ejphar.2018.06.010. Epub 2018 Jun 7. Review. PubMed PMID: 29886242; PubMed Central PMCID: PMC6057804.
40. Altara R, Ghali R, Mallat Z, Cataliotti A, **Booz GW**, Zouein FA. Conflicting Vascular and Metabolic Impact of the IL-33/sST2 Axis. *Cardiovasc Res.* 2018 Oct 1;114(12):1578-1594. doi: 10.1093/cvr/cvy166. PMID: 29982301.
41. Forrester SJ, **Booz GW**, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R, Eguchi S. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. *Physiol Rev.* 2018 Jul 1;98(3):1627-1738. doi: 10.1152/physrev.00038.2017. PubMed PMID: 29873596.
42. Kaplan A, Abidi E, El-Yazbi A, Eid A, **Booz GW**, Zouein FA. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. *Heart Fail Rev.* 2018 May;23(3):419-437. doi: 10.1007/s10741-017-9665-9. Review. PubMed PMID: 29322280.
43. Lv W, **Booz GW**, Fan F, Wang Y, Roman RJ. Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies. *Front Physiol.* 2018 Feb 16;9:105. doi: 10.3389/fphys.2018.00105. eCollection 2018. Review. PubMed PMID: 29503620; PubMed Central PMCID: PMC5820314.
44. Lv W, **Booz GW**, Wang Y, Fan F, Roman RJ. Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets. *Eur J Pharmacol.* 2018 Feb 5;820:65-76. doi: 10.1016/j.ejphar.2017.12.016. Epub 2017 Dec 8. Review. PubMed PMID: 29229532.
45. Ghali R, Altara R, Louch WE, Cataliotti A, Mallat Z, Kaplan A, Zouein FA, **Booz GW**. IL (Interleukin)-33/sST2 Axis in Hypertension and Heart Failure. *Hypertension.* 2018 Oct;72(4):818-828. PMID: 30354724.
46. Kurdi M, Zgheib C, **Booz GW**. Recent Developments on the Crosstalk Between STAT3 and Inflammation in Heart Function and Disease. *Front Immunol.* 2018;9:3029. PMID: 30619368.
47. Zouein FA, **Booz GW**, Altara R. STAT3 and Endothelial Cell – Cardiomyocyte Dialog in Cardiac Remodeling. *Front Cardiovasc Med* 2019 Apr 24;6:50. PMID: 31069236
48. Shekhar S, Varghese K, Li M, Fan L, **Booz GW**, Roman RJ, Fan F. Conflicting Roles of 20-HETE in Hypertension and Stroke. *Int J Mol Sci.* 2019;20. pii: E4500. PMID: 31514409.
49. Harhous Z, **Booz GW**, Ovize M, Bidaux G, Kurdi M. An Update on the Multifaceted Roles of STAT3 in the Heart. *Front Cardiovasc Med.* 2019;6:150. PMID: 31709266.
50. Bejjani AT, Saab SA, Muhieddine DH, Habeichi N, **Booz GW**, Zouein FA. Cardiac Spatiotemporal Dynamics of Major Immune Cells and Cytokines During Early Left Ventricular Remodeling Post-Myocardial Infarction in Mice. *J Cardiovasc Pharmacol.* 2020;75:112-122. doi: 10.1097/FJC.0000000000000777. PMID: 31764396
51. Nourredine F, Altara R, Fan F, Yabluchanskiy A, **Booz GW**, Zouein FA. Impact of the Renin-Angiotensin System on the Endothelium in Vascular Dementia: Unresolved Issues and Future Perspectives. *Int J Mol Sci.* 2020. PMID: 32560034
52. Tannous C, **Booz GW**, Altara R, Muhieddine DH, Mericksay M, Refaat M, Zouein FA. Nicotinamide Adenine Dinucleotide: Biosynthesis Pathways, Consuming Enzymes, and Therapeutic Role in Cardiac Diseases. *Acta Physiol (Oxf).* 2020 Aug 27:e13551. doi: 10.1111/apha.13551. PMID: 32853469
53. **Booz GW**, Altara R, Eid AH, Wehbe Z, Fares S, Zaraket H, Habeichi NJ, Zouein FA. Macrophage Responses Associated with COVID-19: A Pharmacological Perspective. *Eur J Pharmacol.* 2020 Sep 11;887:173547. doi:10.1016/j.ejphar.2020.173547. PMID: 32919938

54. Smith AN, Thomas DG, Tatum RE, **Booz GW**, Cunningham MW Jr. The Role of Mitochondrial Dysfunction in Preeclampsia: Causative Factor or Collateral Damage? *Am J Hypertens*. 2021 May 22;34(5):442-452. doi: 10.1093/ajh/hpab003. PMID: 33417666.
55. Shekhar S, Liu Y, Wang S, Zhang H, Fang X, Zhang J, Fan L, Zheng B, Roman RJ, Wang Z, Fan F, **Booz GW**. Novel Mechanistic Insights and Potential Therapeutic Impact of TRPC6 in Neurovascular Coupling and Ischemic Stroke. *Int J Mol Sci*. 2021 Feb 19;22(4):2074. doi: 10.3390/ijms22042074. PMID: 33669830; PMCID: PMC7922996.
56. Jiao F, Varghese K, Wang S, Liu Y, Yu H, **Booz GW**, Roman RJ, Liu R, Fan F. Recent Insights Into the Protective Mechanisms of Paeoniflorin in Neurological, Cardiovascular, and Renal Diseases. *J Cardiovasc Pharmacol*. 2021 Jun 1;77(6):728-734. doi: 10.1097/FJC.0000000000001021. PMID: 34001724; PMCID: PMC8169546.
57. da Silva GJJ, Altara R, **Booz GW**, Cataliotti A. Atrial Natriuretic Peptide₃₁₋₆₇: A Novel Therapeutic Factor for Cardiovascular Diseases. *Front Physiol*. 2021 Jul 8;12:691407. doi: 10.3389/fphys.2021.691407. PMID: 34305645; PMCID: PMC8297502.
58. Habeichi NJ, Tannous C, Yabluchanskiy A, Altara R, Mericskay M, **Booz GW**, Zouein FA. Insights into the modulation of the interferon response and NAD⁺ in the context of COVID-19. *Int Rev Immunol*. 2021 Aug 11:1-11. doi: 10.1080/08830185.2021.1961768. Epub ahead of print. PMID: 34378474.

Editorial Commentaries/Perspectives

1. **Booz GW**. The cardiac angiotensin AT₂ receptor, what exactly does it do? *Hypertension*. 43: 1162-1163, 2004.
2. **Booz GW**. Growing old, angiotensin II, cardiac hypertrophy, and death: making the connection with p66^{Shc}. *Hypertension* 46: 259-260, 2005.
3. **Booz GW**. Impact of T-Lymphocytes on Cardiac Remodeling in Hypertension: More Questions than Answers. *Hypertension* 2006;48(1):31-2.
4. **Booz GW**. Review of: Heart Failure: Molecules, Mechanisms, and Therapeutic Targets, (Novartis Foundation Symposium 274). *Congest. Heart Failure* 2007;13:62-63.
5. **Booz GW**. Devising New Drugs for the Treatment of Hypertension - "Novel Drugs Targeting Hypertension: Renin Inhibitors and Beyond" *J. Cardiovasc. Pharmacol*. 2007;50:1-2.
6. Kurdi M, **Booz GW**. Growing hearts by the bushel. *Congest. Heart Failure* 2008;14:95-96.
7. **Booz GW**. Novel drugs targeting hypertension revisited. *J Cardiovasc Pharmacol*. 2010;56:213-4.
8. Kurdi M, **Booz GW**. Focus on Mitochondria Dysfunction and Dysregulation in Heart Failure: Towards New Therapeutic Strategies to Improve Heart Function. *Congest. Heart Failure* 2011;17:255-6.
9. Zouein FA, Kurdi M, **Booz GW**. HSPA12B and Repairing the Heart: Beauty in Simplicity. *Cardiovasc Res*. 2013;99:587-589.
10. Kurdi M, **Booz GW**. Carvedilol Protects the Infarcted Heart by Upregulating miR-133: First Evidence that Disease State Affects β -Adrenergic Arrestin-Biased Signaling? *J Mol Cell Cardiol*. 2014;76:12-4.
11. Altara R, **Booz GW**. Deleting Vascular ADAM17 Sheds New Light on Hypertensive Cardiac Hypertrophy. *Hypertension*. 2016;68:849-50. doi: 10.1161/HYPERTENSIONAHA.116.07715. PubMed PMID: 27480838.
12. Altara R, Didion SP, **Booz GW**. Conflicting mechanisms of AT₂ cardioprotection revealed. *Cardiovasc Res*. 2016;112:426-8. doi: 10.1093/cvr/cvw199. PubMed PMID: 27659501;

PubMed Central PMCID: PMC5031951.

13. **Booz GW**. A Few Initial Thoughts on Receiving the Baton. *J Cardiovasc Pharmacol*. 2018 Jul;72(1):2. doi: 10.1097/FJC.0000000000000601. PubMed PMID: 29975326.
14. **Booz GW**. Seizing the Future: What's Next for the Journal of Cardiovascular Pharmacology? *J Cardiovasc Pharmacol*. 2019 Jan;73(1):1-2. PMID: 30383608.
15. Hill JA, Agewall S, Baranchuk A, **Booz GW**, Borer JS, Camici PG, Chen PS, Dominiczak AF, Erol Ç, Grines CL, Gropler R, Guzik TJ, Heinemann MK, Iskandrian AE, Knight BP, London B, Lüscher TF, Metra M, Musunuru K, Nallamothu BK, Natale A, Saksena S, Picard MH, Rao SV, Remme WJ, Rosenson RS, Sweitzer NK, Timmis A, Vrints C. Medical misinformation: vet the message!
Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):62-63. PMID:30689786.
Eur Heart J Qual Care Clin Outcomes. 2019 Apr 1;5(2):83-84. PMID:30689789;
Heart Rhythm. 2019 Mar;16(3):332-333. PMID: 30703343.
Hypertension. 2019 Mar;73(3):506-507. PMID: 30686083.
J Interv Card Electrophysiol. 2019 Feb 23. PMID: 30798439.
Anatol J Cardiol. 2019 Feb;21(2):58-59. PMID: 30694814.
Circ Cardiovasc Imaging. 2019 Feb;12(2):e008809. PMID: 30688516.
Circ Cardiovasc Interv. 2019 Feb;12(2):e007796. PMID: 30688520.
Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e005496. PMID: 30688519.
Circ Genom Precis Med. 2019 Feb;12(2):e002439. PMID: 30688515.
Circ Heart Fail. 2019 Feb;12(2):e005869.PMID: 30688079.
Eur Heart J. 2019 Feb 1;40(5):404-405. doi: 10.1093/eurheartj/ehz009. PMID: 30689805
J Cardiovasc Pharmacol. 2019 Feb;73(2):61-62. PMID: 30730472.
Circulation. 2019 Jan 29;139(5):571-572. PMID: 30689419.
Cardiovasc Res. 2019 Jan 28. PMID: 30689762.
J Interv Card Electrophysiol. 2019 Jun;55(1):1-3. doi: 10.1007/s10840-019-00511-4.
16. Abbate A, **Booz GW**. Cardiovascular Pharmacology of the NLRP3 Inflammasome. *J Cardiovasc Pharmacol* 2019;74:173-174. PMID: 31498192.
17. Altara R, **Booz GW**. Editorial: Cardiac Microvascular Endothelium Contribution to Cardiac Myocyte Growth, Structure, and Contractile Function. *Front Cardiovasc Med*. 2019;6:130. doi: 10.3389/fcvm.2019.00130. eCollection 2019. PubMed PMID: 31552274; PubMed Central PMCID: PMC6735222.
18. Lukowski R, **Booz GW**. Deciphering the dynamics and therapeutic potential of the cardiac cGMP cascade: An update on where we are and what we need to know. *J Cardiovasc Pharmacol*. 2020 Feb 25. doi: 10.1097/FJC.0000000000000814. [Epub ahead of print] PubMed PMID: 32106180.
19. Zouein FA, **Booz GW**. Targeting mitochondria to protect the heart: a matter of balance? *Clin Sci (Lond)*. 2020 Apr 17;134(7):885-888. doi: 10.1042/CS20200236. PubMed PMID: 32286622.
20. Altara R, Zouein FA, **Booz GW**. Untangling the Interplay between Mitochondrial Fission and NF-κB Signaling in Endothelial Inflammation. *Hypertension*. 2020;76:23-25. PMID: 32520615.
21. Kurdi M, Pollesello P, **Booz GW**. Levosimendan Comes of Age: Twenty Years of Clinical Use. *J Cardiovasc Pharmacol*. 2020. May 11. Online ahead of print. PMID: 32433361.
22. **Booz GW**, Zouein FA. Science unites a troubled world: Lessons from the pandemic. *Eur J Pharmacol*. 2021 Jan 5;890:173696. doi: 10.1016/j.ejphar.2020.173696. Epub 2020 Oct 29. PMID: 33130278; PMCID: PMC7598756.
23. Zouein FA, Altara R, Massoud GP, **Booz GW**. The Angiotensin II Type 1(AT1) Receptor and

- Cardiac Hypertrophy: Did We Have It Wrong All Along? *J Cardiovasc Pharmacol.* 2021 May 1;77(5):531-535. doi: 10.1097/FJC.0000000000000999. PMID: 33657051.
24. Fan F, **Booz GW**, Roman RJ. Aging diabetes, deconstructing the cerebrovascular wall. *Aging (Albany NY).* 2021 Apr 12;13(7):9158-9159. doi: 10.18632/aging.202963. Epub 2021 Apr 12. PMID: 33846281; PMCID: PMC8064220.
 25. **Booz GW**, Massoud GP, Altara R, Zouein FA. Unravelling the impact of intrauterine growth restriction on heart development: insights into mitochondria and sexual dimorphism from a non-hominoid primate. *Clin Sci (Lond).* 2021 Jul 30;135(14):1767-1772. doi: 10.1042/CS20210524. PMID: 34313297.

Book Chapters

1. **Booz GW**, Baker KM. Protein phosphorylation. In: *Hypertension Primer: The Essentials of High Blood Pressure* (2nd ed), Senior Editors: J. L. Izzo and H. R. Black. Baltimore, Maryland: Lippincott Williams & Wilkins, 1999, pp. 71-75.
2. **Booz GW**, Baker KM. Protein phosphorylation. In: *Hypertension Primer: The Essentials of High Blood Pressure* (3rd ed), Senior Editors: J. L. Izzo and H. R. Black. Baltimore, Maryland: Lippincott Williams & Wilkins, 2003, pp. 92-96.
3. **Booz GW**, Baker KM. Intracellular signaling and the cardiac renin angiotensin system. In: De Mello WC, ed. *Renin Angiotensin System and the Heart*. West Sussex, England: John Wiley & Sons; 2004: 1-17.
4. **Booz GW**. Left ventricular physiology in hypertension. In: *Comprehensive Hypertension*. Editors: Y. H. Lip and J. E. Hall. Mosby, 2007, Chapter 10, pp.113-121.
5. **Booz GW**, Baker KM. Protein phosphorylation. In: *Hypertension Primer: The Essentials of High Blood Pressure* (4th ed), Senior Editors: J. L. Izzo and H. R. Black. Baltimore, Maryland: Lippincott Williams & Wilkins 2008, pp. 16-21.
6. **Booz GW**. Oxidative Stress and Heart Failure: Still a Viable Therapeutic Target? In: García JE, Wright VR eds. *Congestive Heart Failure: Symptoms, Causes and Treatment*. Hauppauge, New York: Nova Science Publishers; 2010: 89-109.
7. Abidi E, Kaplan A, **Booz GW**, Zouein FA. Oxidative Stress in Cardiac Remodeling Post-Ischemia/Reperfusion: Friend or Foe? In: *Oxidative Stress in Heart Diseases*. Editors: S. Chakraborti, NS Dhalla, NK Ganguly, M Dikshit. Springer, Singapore (2019); pp 253-28; <https://doi.org/10.1007/978-981-13-8273-4>; Print ISBN 978-981-13-8272-7; Online ISBN 978-981-13-8273-4
8. **Booz GW**, Altara R, Didion SP. JAK-STAT Signaling in Cardiovascular Disease. In: *JAK-STAT Signaling in Diseases*. Editor: R Goswami. CRC Press (March 12, 2020). ISBN 9781138487628. Chapter 7.
9. Massoud GP, Eid A, **Booz GW**, Rached L, Yabluchanskiy A, Zouein FA#. (2021). *Senolytics in Diseases: Killing to Survive*. Springer. (Under review).
10. Zouein FA, LaMarca BB, **Booz GW**. Protective role of the AT1 Receptor in the Heart: a Biosensor of Stress (Submitted).

Abstracts

1. **Booz G**, Pritchard JB, Kleinzeller A. The renal clearance of D-mannose in the winter flounder. *Bull. Mt. Desert Isl. Biol. Lab.* 17:44-5, 1977.
2. **Booz G**, Pew DE, Kleinzeller A. The renal handling of D-fructose by the winter flounder (*Pseudopleuronectes americanus*). *Bull. Mt. Desert Isl. Biol. Lab.* 18: 26, 1978.

3. **Booz G**, Goldstein J, Pritchard J, Kleinzeller A. The handling of D-mannose at the brush border of the kidney in the winter flounder (*Pseudopleuronectes americanus*). *Bull. Mt. Desert Isl. Biol. Lab.* 18: 26-8, 1978.
4. **Booz G**, Dornbusch J, Goldstein J, Murdaugh A, Forrest JN, Kleinzeller A. Experiments on the cell volume regulation in slices of the rectal gland of the dogfish (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 18:23-5, 1978.
5. **Booz G**. Renal clearance of DMO and methylamine by the winter flounder (*Pseudopleuronectes americanus*). *Bull. Mt. Desert Isl. Biol. Lab.* 18:25-6, 1978.
6. **Booz G**, Beyenbach K, Kleinzeller A. Methylamine secretion by isolated perfused renal tubules of the winter flounder (*Pseudopleuronectes americanus*). *Bull. Mt. Desert Isl. Biol. Lab.* 20: 66-8, 1980.
7. Beyenbach KW, **Booz G**, Kleinzeller A. Transepithelial voltages and resistances across isolated perfused renal tubules of the winter flounder. *Bull. Mt. Desert Isl. Biol. Lab.* 20: 78-82, 1980.
8. Kleinzeller A, Mills JW, **Booz G**, Davis SJ. Effects of p-chloromercuribenzenesulfonate (PCMBs) on the volume maintenance of dogfish (*Squalus acanthias*) rectal gland cells. *Bull. Mt. Desert Isl. Biol. Lab.* 26: 163-4, 1986.
9. Stanley CA, Corkey BE, **Booz G**, Hale DE, Glennon MC, Berry GT. Hepatic acyl CoA profiles in riboflavin-induced multiple acyl-CoA dehydrogenase deficiency. *Pediatr. Res.* 348A, 1987.
10. Ziyadeh FN, Feldman GM, **Booz GW**, Kleinzeller A. Uptake of trimethylamine-N-oxide (TMAO) and trimethylamine (TMA) in skeletal muscle and rectal gland of shark (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 27: 44, 1987-88.
11. Ziyadeh FN, Feldman GM, **Booz GW**, Kleinzeller A. Taurine uptake and efflux in rectal gland cells of shark (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 27: 94, 1987-88.
12. Feldman GM, Ziyadeh FN, **Booz GW**, Mills JW, Kleinzeller A. Iso-osmotic cell swelling induced by propionate in rectal gland of shark (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 27: 108-9, 1987-88.
13. **Booz GW**, Ziyadeh FN, Feldman GM, Kleinzeller A. The binding sites involved in p-chloromercuribenzenesulfonate (PCMBs) induced swelling of dogfish (*Squalus acanthias*) rectal gland cells. *Bull. Mt. Desert Isl. Biol. Lab.* 27: 1-3, 1987-88.
14. **Booz GW**, Feldman GM, Mills JW, Kleinzeller A. Cation specificity in cell volume maintenance in rectal gland cells of the dogfish (*Squalus acanthias*). *Bull. Mt. Desert Isl. Biol. Lab.* 27: 124-5, 1987-88.
15. Feldman GM, Ziyadeh FN, **Booz GW**, Kleinzeller A. Iso-osmotic cell swelling induced by propionate. *Kidney Int.* 33: 418, 1988.
16. Ziyadeh FN, Mills JW, **Booz GW**, Kleinzeller A. Recovery of cell volume and solute composition following potassium-induced swelling in rectal gland cells of the shark (*Squalus acanthias*): Properties of the system. *Bull. Mt. Desert Isl. Biol. Lab.* 28: 68-9, 1989.
17. Feldman GM, Ziyadeh FN, **Booz GW**, Kleinzeller A. Cell swelling induced by an organic anion. *Kidney Int.* 35: 495, 1989.
18. **Booz GW**, Kleinzeller A, Payne J. Hexose transport by dogfish (*Squalus acanthias*) and flounder (*Pseudopleuronectes americanus*) erythrocytes. *Bull. Mt. Desert Isl. Biol. Lab.* 28: 47, 1989.
19. Kleinzeller A, Ziyadeh FN, **Booz GW**, McCallum S. Role of the Na, K-ATPase in the mercurial-induced swelling of dogfish (*Squalus acanthias*) rectal gland cells. *Bull. Mt. Desert Isl. Biol. Lab.* 29: 67, 1990.
20. **Booz GW**, Kleinzeller A. Hexose transport by flounder (*Pseudopleuronectes americanus*) erythrocytes. *Bull. Mt. Desert Isl. Biol. Lab.* 29: 52, 1990.

21. **Booz GW**, Bianchi CP. N-Carbobenzoxy-glycyl-L-phenylalaninamide inhibits both basal and contraction-initiated 2-deoxyglucose uptake by frog muscle. *FASEB J.* 4: A541, 1990.
22. **Booz GW**, Kleinzeller A. 2-Deoxyglucose uptake by flounder (*Pseudopleuronectes americanus*) erythrocytes. *Bull. Mt. Desert Isl. Biol. Lab.* 30: 50, 1991.
23. Kleinzeller A, **Booz GW**, Ziyadeh FN. The effect of medium composition on the anisoosmotic volume response of dogfish (*Squalus acanthias*) rectal gland cells. *Bull. Mt. Desert Isl. Biol. Lab.* 30: 76-77, 1991.
24. **Booz G**, Shetlar R, Morrison-Shetlar A. Anoxia affects the membrane cytoskeleton of flounder (*Pseudopleuronectes americanus*) erythrocytes. *Bull. Mt. Desert Isl. Biol. Lab.* 31: 14-15, 1992.
25. **Booz GW**, Conrad KM, Hess AL, Baker KM. Angiotensin II binding sites on hepatocyte nuclei. *FASEB J.* 6: A1577, 1992.
26. Schorb W, **Booz GW**, Dostal DE, Chang KC, Baker KM. Angiotensin II receptor mediated growth of cardiac fibroblasts. *Circulation* 86: A189, 1992.
27. Thekkumkara TJ, Du J, Dostal DE, **Booz GW**, Motel TJ, Baker KM. Characterization of permanently transfected AT_{1A} receptors in CHO-K1 cells: Desensitization by angiotensin II. *FASEB J.* 7: A491, 1993.
28. **Booz GW**, Singer HA, Baker KM. Role of protein kinase C in angiotensin II-induced mitogenesis of neonatal rat cardiac fibroblasts. *The Physiologist* 36:A-11, 1993.
29. Taher MM, **Booz GW**, Baker KM, Singer HA. Angiotensin-induced phosphatidic acid in cardiac fibroblasts. *J. Mol. Cell. Cardiol.* 26: CLV(Abstr. #19), 1994.
30. **Booz GW**, Reiprish MJ, Baker KM. AT₂ receptor blockade augments angiotensin II-induced cardiomyocyte hypertrophy. *Hypertension* 26: 547 (#61), 1995.
31. Lin C, Baker KM, Rothblum KN, **Booz GW**, Dostal DE. Atrial natriuretic peptide regulation of renin and angiotensinogen mRNA in cultured rat ventricular cardiac fibroblasts. *Hypertension* 26: 562 (#P64), 1995.
32. Fukuzawa J, Dostal DE, **Booz GW**, Hunt RA, Kempinski AM, Baker KM. Cardiotrophin-1 induces cardiomyocyte hypertrophy through stimulation of the renin-angiotensin system. *J. Am. Coll. Cardiol.* 2 (Suppl A):315A, 1999.
33. **Booz GW**, Smith JD, Baker KM. Angiotensin II inhibits gp130 signaling in cardiac myocytes by tyrosine phosphatase activation. *J. Am. Coll. Cardiol.* 37 (Suppl A): 239A, 2001.
34. Fukuzawa J, Baker KM, **Booz GW**. Negative modulation of angiotensin II-induced Jak/STAT signaling in cardiomyocytes via stable complex formation of protein tyrosine phosphatase SHP-2 with STAT3. *J. Am. Coll. Cardiol.* 37 (Suppl A): 295A, 2001.
35. **Booz GW**, Day JNE, Baker KM. Endothelin-1 inhibits activation of the LIF receptor in cardiomyocytes. *Hypertension* 38: 529 (P219), 2001.
36. Kule CE, Karoor V, Day JNE, Thomas WG, Baker KM, Acker KA, **Booz GW**. Rescue of internalization-impaired angiotensin II AT₁ mutants by β -arrestin overexpression. *J. Am. Coll. Cardiol.* 43 (Suppl A): 455A, 2004.
37. Salamat N, Maxwell SA, Brewer JR, Day JNE, Winn RE, **Booz GW**. Activation of STAT1 BY IFN- γ Inhibits Growth of Human Non-Small Cell Lung Cancer Cells. *Chest* 126 : 914S, 2004.
38. Day JNE, **Booz GW**. The Anti-Inflammatory Agent Parthenolide has Differential and Independent Effects on Jak-STAT and ERK Signaling in Cardiac Myocytes. *Hypertension* 44 (Oct): P9, 2004.
39. Day JNE, **Booz GW**. Molecular mechanisms of IL-6-related-cytokine STAT3 regulation in cardiac myocytes. *J Cardiac Failure* 10 (Suppl 4): 121, 2004.
40. Brewer JR, Guthrie NS, **Booz GW**. Interferon- γ has a potent cytostatic effect via STAT1 activation on the A549 human lung cancer cell line. *Mol Cell Biol* 15: 370a (#2047), 2004.
41. Kurdi M, Nickolai JL, **Booz GW**. Anti-inflammatory parthenolide inhibits JAK1 activation in cardiac myocytes but induces oxidative stress. *J. Mol. Cell. Cardiol.* 38: 845 (#99), 2005.

42. Brewer JR, Spradley C, Nickolai JL, Winn RE, **Booz GW**. Role of STAT1 in the Permissive Effect of Interferon- γ on FAS-Induced Apoptosis of Non-Small Cell Lung Cancer Cells. *Chest* 128: 154S, 2005.
43. Bowers M, Kurdi M, Nickolai JL, **Booz GW**. Parthenolide induces oxidative stress in cardiomyocytes: Differential activation of mitochondrial and NADPH oxidases. *J Cardiac Failure* 11 (Suppl 6): 070, i2005.
44. Prakash G, **Booz GW**. Role for STAT3 in apoptosis signaling by interferon- γ in human nonsmall cell lung cancer A549 cells. *Proc Am Thorac Soc* 3 (Abstract Issue), A175, 2006.
45. Kurdi M, **Booz GW**. Inhibition of IL-6-type cytokine signaling by oxidative stress in cardiac myocytes. *J. Mol. Cell. Cardiol.* 40: 883 (#95), 2006.
46. Kurdi M, **Booz GW**. Oxidative stress blocks activation of JAK-STAT signaling in cardiac myocytes. *J. Mol. Cell. Cardiol.* 42(S1):S50, 2007.
47. Zgheib C, Sebastian T, Tocchetti CG, Paolucci N, King SB, Kurdi M, **Booz GW**. Nitroxyl activates redox-sensitive stress signaling in endothelial cells and has anti-inflammatory actions. *Hypertension* 2010;56:P351.
48. Zgheib C, Sebastian T, Chidiac R, Keen HL, Kurdi M, **Booz GW**. Protein phosphatase 2A (PP2A) plays a critical role determining the endothelial cell gene expression profile of leukemia inhibitory factor (LIF). *Hypertension* 2010;56:O31.
49. Alturkmani HJ, Zgheib C, Zouein FA, Kurdi M, **Booz GW**. Sodium Selenate Enhances Endothelial Cell STAT3 Tyrosine Phosphorylation and DNA Binding. *Mol. Biol. Cell* 2010;21:4299 (#2971/L077).
50. Zouein FA, Sebastian T, Farley JM, **Booz GW**. Transient Receptor Potential Type C Channels Play a Critical Role in Angiogenesis. *FASEB J* 2011;25:1091.12
51. Allukian M, Herdrich BJ, Xu J, Wu W, Dorsett-Martin W, **Booz G**, Mitchell ME, Gorman JH, Gorman RC, Liechty KW. Decreased Inflammation During Cardiac Regeneration Following Fetal Myocardial Infarction (MI) Is Associated with Decreased NF- κ B Expression Compared to the Adult. American College of Surgeons' 97th Annual Clinical Congress
52. Arany I, Reed D, Grifoni SC, **Booz G**, Juncos LA. A novel U-STAT3-dependent regulation of TGF β 1-induced renal tubular epithelial-mesenchymal transition by chronic nicotine exposure. The American Society of Nephrology 2011.
53. Arany I, Clark K, Reed D, **Booz G**, Juncos LA Sex hormones modulate responses to oxidative stress in renal proximal tubule cells. 2011 APS Conference: Physiology of Cardiovascular Disease: Gender Disparities.
54. Zouein FA, Zgheib C, Hamza S, Hall JE, Ruiz A, Juncos L, **Booz GW**. DUAL ROLE OF STAT3 IN HYPERTENSION-INDUCED CARDIAC REMODELING. *The FASEB Journal.* 2012;26:1060.19.
55. Zouein F, Zgheib C, Fuseler J, Hall JE, Kurdi M, **Booz GW**. STAT3 Affects Myofibrillar Structure and Its Loss May Contribute to Heart Failure in Hypertension. *Hypertension.* 2012;60:A71.
56. Zgheib C, Kurdi M, Zouein F, Zgheib J, King S, Paolucci N, **Booz GW**: Acyloxy Nitroso Compounds Inhibit LIF Signaling in Endothelial Cells and Cardiac Myocytes: Evidence That STAT3 Signaling is Redox-Sensitive. *Hypertension.* 2012;60:A219
57. Fuseler JW, Zouein FA, Kurdi M, **Booz GW**. Fractal and Image Analysis of Collagen Fibrosis in Hypertensive Induced Myocardial Remodeling in Mouse Hearts Lacking STAT3 Protection. *Microscopy & Microanalysis.* 2013
58. Zouein FA, Kurdi M, **Booz GW**, Fuseler JW. Role of STAT3 in Collagen Deposition and Organization in the Normal and Hypertensive Heart. *Hypertension.* 2013;62:A387. Abstract. Available at:
http://hyper.ahajournals.org/cgi/content/meeting_abstract/62/3_MeetingAbstracts/A387.
59. Zouein FA, Zgheib C, do Carmo JM, Vaka R, Altara R, Kurdi M, **Booz G**. Abstract 110:

Importance of the C-Terminal Transactivation Domain of STAT3 in Hypertension-Induced Cardiac Hypertrophy. *Hypertension*. 2015;66:A110. Available:

http://hyper.ahajournals.org/content/66/Suppl_1

60. Wang S, Feng J, He X, **Booz G**, Roman RJ and Fan F. *Hyperglycemia induces impairment of cerebral autoregulation in association with cognitive deficits in diabetic rats. 2018 NIH, NIGMS Seveth Biennial Natioanal IDeA Symposium of Biomedical Research Excellence, Washington, D.C.*
61. Wang S, Feng J, He X, **Booz G**, Roman RJ and Fan F. Disruption of Actin Cytoskeleton Contributes to Impairment of Cerebral Autoregulation in Association with Diabetes-related Cognitive Deficits. 2018, 11th World Congress for Microcirculation, Vancouver, BC, Canada.
62. Fan F, Wang S, He X, **Booz G** and Roman RJ. Down Regulation of Gamma-Adducin in the Cerebral Vasculature Promotes Blood-Brain Barrier Leakage and Contributes to Hypertension-related Cognitive Deficits. 2018, 11th World Congress for Microcirculation, Vancouver, BC, Canada.
63. Zhang C, He X, Wang S, Roman RJ, **Booz G** and Fan F. Knockout of Dual-Specificity Protein Phosphatase 5 Protects Against Hypertension Induced Chronic Kidney Disease. 2018 Joint Hypertension 2018 Scientific Sessions, Chicago, IL.
64. Wang S, He X, **Booz G**, Roman RJ and Fan F. Hyperglycemia and Oxidative stress Contribute to Impaired Cerebral Autoregulation in Association with Dementia in Diabetes. 2018 Joint Hypertension 2018 Scientific Sessions, Chicago, IL.
65. Zhang C, He X, **Booz GW**, Roman RJ, Fan F. Knockout of Dual-Specificity Protein Phosphatase 5 Protects Against Hypertension Induced Chronic Kidney Disease. 2018 HBPR, Chicago, IL
66. He X, Chen CCA, Murphy SR, **Booz GW**, Roman RJ, Fan F. Hypertensin-induced renal injury is associated with impaired glomerular barrier function involving podocyte dysfunction. *Experimental Biology* 2019, Orlando, FL. *The FASEB Journal* 33 (1_supplement), 573.9-573.9
67. Wang S, Jiao F, Guo Y, **Booz G**, Roman R, Fan F. Role of Vascular Smooth Muscle Cells in Diabetes-related Vascular Cognitive Impairment. *Stroke*, 2019
68. Cunningham Jr. MW, Jayaram A, Amaral LA, Chinthakuntla P, Brooks K, **Booz G**, Vaka VR, Ibrahim T, Deer E, Cornelius DC, LaMarca B. Tumor Necrosis Factor Alpha Blockade Improves Natural Killer Cell Activation, Hypertension, and Mitochondrial Oxidative Stress in a Preclinical Rat Model of Preeclampsia. *Hypertension* 2019 Scientific Session. P1110.
69. Cunningham Jr MW, Chinthakuntla P, Brooks K, Fisher B, Ibrahim T, Amaral LM, **Booz GW**. Angiotensin II type I receptor agonistic autoantibody blockade improves hypertension and immune activation in postpartum preeclamptic rats. *Hypertension* 2019.
70. Gao W, Zhang H, He X, Wang S, Ya G, **Booz GW**, Roman RJ, Fan F. Dual-Specificity Protein Phosphatase 5 Regulates Renal Vessel Myogenic Response via Direct Modulating Extracellular Signal-Related Kinase and Protein Kinase C. *Hypertension* 2019 Scientific Session. P160.
71. Guo Y, Wang S, Zhang H, Gao W, He X, **Booz GW**, Roman RJ, Fan F. High Glucose Induced Diabetic Dementia is Mediated by Mitochondria Dysfunction. *Hypertension* 2019 Scientific Session. P3016.
72. Altara R, da Silva G, Frisk M, Norden E, Bergo K, Sjaastad I, Geimer T, Mahan L, Louch W, **Booz GW**, Cataliotti A. Cardiorenal and Humoral Actions of proANP₃₁₋₆₇ (Vastiras®) in Diastolic Dysfunction. *CHFR Symposium - Holmenkollen, Oslo Sept 2018* (poster).

73. Altara R, da Silva GJJ, Frisk M, Norden ES, Spelta F, Espe EKS, Sjaastad I, Zouein F, Louch W, **Booz GW**, Cataliotti A. Cardiorenal Protective Effects of ProANP₃₁₋₆₇ Independent of Blood Pressure. Norwegian Society of Hypertension. 7 Feb. 2019, Oslo (oral).
74. Altara R, da Silva GJJ, Frisk M, Norden ES, Spelta F, Espe EKS, Sjaastad I, Zouein FA, Louch WE, **Booz GW**, Cataliotti A. Cardiorenal Protective Effects of Pro-ATRIAL-NATRIURETIC-PEPTIDE (31-67) Independent of Blood Pressure. Annual ESH 2019, Milan (oral and poster). [HTTPS://JOURNALS.LWW.COM/JHYPERTENSION/ABSTRACT/2019/07001/CARDIORENAL_PROTECTIVE_EFFECTS_OF.69.ASPX](https://journals.lww.com/jhypertension/abstract/2019/07001/cardiorenal_protective_effects_of.69.aspx)
75. Altara R, da Silva GJJ, Frisk M, Norden ES, Spelta F, Espe EKS, Sjaastad I, Zouein FA, Louch WE, **Booz GW**, Cataliotti A. THE PROTECTIVE EFFECTS OF PRO-ATRIAL-NATRIURETIC-PEPTIDE (31-67) ON HYPERTENSION INDUCED CARDIAC AND RENAL ADVERSE REMODELING. 2019 XXIII ISHR World Congress, Beijing (poster).
76. Altara R, da Silva GJJ, Frisk M, Zouein FA, Louch WE, **Booz GW**, Cataliotti A, Low dose of proANP₃₁₋₆₇ does not affect kidney function/structure, but prevents adverse cardiac remodeling independent of blood pressure regulation. Heart Failure 2020 - European Society of Cardiology (poster for online meeting).